




# **Effect of Pomegranate Juice on Lipid Profile and Antioxidant Enzymes in Hypercholesterolemic Rats**

**By:**

**Manal Moalla Dugilib AL-Moraie**

**A thesis Submitted for the Requirements of the Degree of Master of Science [Food and Nutrition]**

**FACULTY OF HOME ECONOMICS  
KING ABDULAZIZ UNIVERSITY, JEDDAH  
Rajab 1434 H- May 2013 G**





# **Effect of Pomegranate Juice on Lipid Profile and Antioxidant Enzymes in Hypercholesterolemic Rats**

**By:**

**Manal Moalla Dugilib Al-Moraie**

**A thesis Submitted for the Requirements of the Degree of Master of Science [Food and Nutrition]**

**Supervised by:**

**Dr. Reham A. Arafat**

**Dr. Amani A. Al-Rasheedi**

**FACULTY OF HOME ECONOMICS  
KING ABDULAZIZ UNIVERSITY  
JEDDAH-SAUDI ARABIA  
Rajab 1434 H- May 2013 G (18/7/1434H)**

# **Effect of Pomegranate Juice on Lipid Profile and Antioxidant Enzymes in Hypercholesterolemic Rats**

**By:**  
**Manal Moalla Dugilib Al-Moraie.**

**This thesis has been approved and accepted in partial fulfillment of the requirements for the degree of Master of Science [Food and Nutrition]**

## **EXAMINATION COMMITTEE**

	<b>Name</b>	<b>Rank</b>	<b>Field</b>	<b>Signature</b>
Internal Examiner	Dr. Mona A. Farrag	Assistant Prof.	Food & Nutrition	
External Examiner	Dr. Amr A. Rezq	Associate Prof.	Food & Nutrition	
Co-Advisor	Dr. Amani A. AL-Rasheedi	Associate Prof.	Food & Nutrition	
Advisor	Dr. Reham A. Arafat	Associate Prof.	Food & Nutrition	

**KING ABDULAZIZ UNIVERSITY**

**1434H-2013G**

## *Dedication to*

*This thesis is dedicated to:*

*My Parents*

*My Husband*

*My Daughter Hala & Sons Abdulrahman & Mohmmed*

## ACKNOWLEDGMENTS

First and foremost thanks are to **Allah**, the most beneficent and merciful, who without his aid this work couldn't be done.

I am greatly honored to express sincere thanks to my supervisor, Dr. Reham A. Arafat, Associated professor, Food and Nutrition Department, Faculty of Home Economics, King Abdulaziz University, for her indispensable help, direct supervision, suggestion the subject and her advice during this work.

I wish also to express my great thanks to Dr. Amani A. Al-Rasheedi, Associated professor, Food and Nutrition department, Faculty of Art and Design, King Abdulaziz University, for her direct supervision, fruitful assistance and precious advices given throughout this study.

My deepest appreciation and gratefulness is also given to my mother, father, brothers and sisters for their continuous support throughout this study. I can't also forget to express a very warm respect for all my colleagues for their help.

Last but not the least; I wish also to express my great and deep thanks to my husband for his unlimited help during this work and also I would like to thank my lovely children.

# **Effect of Pomegranate Juice on lipid profile and Antioxidant Enzymes in Hypercholesterolemic Rats**

**By**

**Manal Moalla Doelib Al-Moraie**

## **Abstract**

**Objective:** The present study was carried out to investigate the effects of oral administration of Pomegranate juice at three dosage levels (1, 3 and 5 ml/kg b. wt.) to hypercholesterolemic rats for 28 days on body weight gain %, feed efficiency ratio, relative weights of some internal organs, serum levels of total cholesterol (TC), triglycerides (TG), lipoprotein fractions and liver enzymes, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were performed. Antioxidant enzymes, catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GPx,) were determined in homogenate liver. Histopathological examination of liver and heart were also carried out.

**Methods:** Thirty five male Wistar rats were distributed into five equal groups as follows: negative (normal rats), positive (hypercholesterolemic rats) control groups and positive groups orally given Pomegranate juice in doses of 1, 3 and 5 ml/kg b. wt., respectively. **Results:** The results showed that oral administration of Pomegranate juice to hypercholesterolemic rats for 28 days significantly decreased serum levels of TC, TG, low density lipoproteins cholesterol (LDL-c), very low density lipoproteins cholesterol (VLDL-c) and liver enzymes when compared to the control positive group. Levels of high density lipoprotein cholesterol (HDL-c) and antioxidant enzymes were significantly increased as compared to the control positive group. Histopathological examination of liver and heart of Pomegranate juice-treated groups showed amelioration of histological changes caused by high level of cholesterol in the positive control group. **Conclusion:** Results indicated that Pomegranate juice produces potent antiatherogenic and antioxidant effects in hypercholesterolemic rats. This study recommends that drinking Pomegranate juice may be beneficial for patients who suffer from hypercholesterolemia and/or arteriosclerosis.

# تأثير عصير الرمان على صور ليبيدات الدم والإنزيمات المضادة للأكسدة لدى الفئران المصابة بارتفاع الكولسترول

منال معلا المورعي

## المستخلص

**الهدف:** تم إجراء هذه الدراسة لمعرفة تأثير تناول عصير الرمان بثلاث جرعات عن طريق الفم للفئران المصابة بارتفاع مستوى الكولسترول بالدم لمدة ٢٨ يوم على معدل الزيادة في وزن الجسم ونسبة الكفاءة الغذائية والوزن النسبي لبعض الأعضاء الداخلية، وبعض التحليلات البيوكيميائية كمستوى الكولسترول الكلي، الجليسيريدات الثلاثية، الليبوبروتينات وأنزيمات الكبد (أسبرتات أمينو ترانسفيراز و ألانين أمينو ترانسفيراز) في سيرم الدم ومستوى الإنزيمات المضادة للأكسدة (الكاتاليز، سوبرأكسيد ديسميوتيز وجلوتاثيون بيروكسيديز) في أنسجة الكبد المتجانسة وكذلك الفحص الهستوباثولوجي للكبد والقلب.

**الطريقة:** تم توزيع خمسة وثلاثون فأر على خمس مجموعات بالتساوي كالتالي: مجموعة ضابطة سالبة، مجموعة ضابطة موجبة (مصابة بارتفاع مستوى الكولسترول بالدم)، ثلاث مجموعات أخرى مصابة بارتفاع مستوى الكولسترول بالدم وتم إعطاؤهم عصير الرمان عن طريق الفم بثلاث جرعات ١، ٣ و ٥ مل /كجم من وزن الجسم على التوالي.

**النتائج:** أظهرت النتائج أن تناول عصير الرمان عن طريق الفم للفئران المصابة بارتفاع مستوى الكولسترول بالدم لمدة ٢٨ يوم أدى إلى نقص معنوي في مستوى الكولسترول الكلي و الجليسيريدات الثلاثية و الليبوبروتين المنخفض الكثافة و الليبوبروتين المنخفض الكثافة جدا وكذلك إنزيمات الكبد مقارنة بالمجموعة الضابطة الموجبة، بينما كانت هناك زيادة معنوية في كل من الليبوبروتين العالي الكثافة و الإنزيمات المضادة للأكسدة مقارنة بالمجموعة الضابطة الموجبة. وأظهر الفحص الهستوباثولوجي وجود تحسن ملحوظ في التغيرات المرضية التي أحدثها الكولسترول المرتفع بالدم مقارنة بالمجموعة الضابطة الموجبة.

**الخلاصة:** أوضحت النتائج أن عصير الرمان له تأثير فعال كمضاد للأكسدة وكذلك للكولسترول في الفئران المصابة بارتفاع الكولسترول بالدم. لذلك توصي الدراسة بتناول عصير الرمان للمرضى الذين يعانون من ارتفاع الكولسترول وكذلك تصلب الشرايين.



## TABLE OF CONTENTS

	Page number
Examination Committee Approval	
<b>Dedication</b>	
<b>Acknowledgements</b> .....	iv
<b>Abstract (English)</b> .....	v
<b>Abstract (Arabic)</b> .....	vi
<b>Table of Contents</b> .....	vii
<b>List of Figures</b> .....	xi
<b>List of Tables</b> .....	xiv
<b>List of Abbreviations</b> .....	xv
<b>CHAPTER I: INTRODUCTION</b>	
1.1 Introduction.....	1
1.2 Aim of the Study.....	4
1.3 Objectives of the Study.....	5

## **CHAPTER II: REVIEW OF LITERATURE**

2.1 Cholesterol.....	6
2.1.1 Hypercholesterolemia.....	7
2.1.1.1 Signs and Symptoms of Hypercholesterolemia.....	10
2.1.1.2 Causes of Hypercholesterolemia.....	11
2.1.2 Antioxidant Enzymes Related to Hypercholesterolemia.....	13
2.2 Pomegranates.....	15
2.2.1 Nutritive Value of Pomegranate.....	17
2.2.1.1 Phenolic Compounds.....	19
2.2.1.2 Tannins.....	23
2.3 Effect of Pomegranate on Blood Lipid.....	25
2.4 Effect of Pomegranate on Liver Function.....	28
2.5 Effect of Pomegranate on Antioxidant Enzymes.....	30
2.6 Safety of Pomegranate.....	36

## **CHAPTER III: MATERIAL AND METHODS**

3.1 Material.....	38
3.1.1 Pomegranate.....	38
3.1.2 Cholesterol.....	38
3.1.3 Rats.....	39
3.1.4 Kits for Biochemical Analysis.....	39
3.2 Methods.....	39
3.2.1 Preparation of the Basal Diet.....	39

3.2.2 Induction of Hypercholesterolemia.....	39
3.2.3 Preparation of Pomegranate Juice.....	40
3.2.4 Experimental Design and Grouping of Rats.....	40
3.2.5 Determination of Feed Intake, Body Weight Gain percent (BWG %) and Feed Efficiency Ratio (FER).....	41
3.2.6 Biochemical Analyses.....	42
3.2.6.1 Estimation of Total Polyphenol Concentration in Pomegranate Juice.....	42
3.2.6.2 Serum Analysis.....	43
3.2.6.2.1 Determination of Serum Total Cholesterol (TC).....	43
3.2.6.2.2 Determination of Serum Triglycerides (TG).....	43
3.2.6.2.3 Determination of High Density Lipoprotein Cholesterol (HDL-c).....	43
3.2.6.2.4 Determination of Low Density Lipoprotein Cholesterol (LDL-c).....	44
3.2.6.2.5 Determination of Very Low Density Lipoprotein Cholesterol (VLDL-c).....	44
3.2.6.2.6 Determination of Liver Enzyme Activity.....	44
3.2.6.2.6.1 Determination of AST and ALT enzyme activity.....	44
3.2.6.3 Determination of Antioxidant Enzyme Activity.....	45
3.2.6.3.1 Determination of Catalase (CAT).....	45
3.2.6.3.2 Determination of Superoxide Dismutase (SOD).....	45
3.2.6.3.3 Determination of Glutathione Peroxidase (GPx).....	46
3.2.7 Histopathological Examination.....	46
3.3 Statistical Analysis.....	46

## **CHAPTER IV: Results**

4.1 Estimation of total polyphenols content of Pomegranate juice.....	47
4.2 Effect of oral administration of Pomegranate juice on initial body weight, final body weight and body weight gain percent (BWG %) in hypercholesterolemic rats.....	48
4.3 Effect of oral administration of Pomegranate juice on feed intake and feed efficiency ratio (FER) in hypercholesterolemic rats.....	53
4.4 Effect of oral administration of Pomegranate juice on liver and heart relative weight in hypercholesterolemic rats.....	57
4.5 Effect of oral administration of Pomegranate juice on the serum levels total cholesterol (TC) and triglycerides (TG) in hypercholesterolemic rats	61
4.6 Effect of oral administration of Pomegranate juice on the serum levels of lipoprotein fractions in hypercholesterolemic rats.....	65
4.∨ Effect of oral administration of Pomegranate juice on serum levels of liver function enzymes in hypercholesterolemic rats.....	71
4.∧ Effect of oral administration of Pomegranate juice on liver homogenates levels of catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GPx) in hypercholesterolemic rats.....	75
4.∩ Histopathological Examination.....	80
4.∩.1 Liver.....	80
4.∩.2 Heart.....	88
<b>CHAPTER V: DISCUSSION.....</b>	<b>94</b>
<b>CHAPTER VI: CONCLUSION AND RECOMMENDATIONS</b>	
6.1 Conclusion.....	105
6.2 Recommendations.....	106
<b>REFERENCES.....</b>	<b>107</b>

## LIST OF FIGURES

<b>Figure</b>		<b>Page number</b>
Figure 2.1	Chemical structural formula of Cholesterol .....	6
Figure 2.2	The development of atherosclerosis.....	9
Figure 2.3	Schematic of formation of reactive oxygen species formation, including points of antioxidant enzyme action.....	14
Figure 2.4	Principal anthocyanins present in Pomegranate juice.....	21
Figure 2.5	Principal phenolic acids present in Pomegranate juice.....	22
Figure 2.6	Principal ellagitannins (ETs) present in pomegranate peels.....	24
Figure 4.1	Effect of oral administration of Pomegranate juice on the initial body weight in hypercholesterolemic rats.....	50
Figure 4.2	Effect of oral administration of Pomegranate juice on the final body weight in hypercholesterolemic rats.....	51
Figure 4.3	Effect of oral administration of Pomegranate juice on the body weight gain percent (BWG %) in hypercholesterolemic rats.....	52
Figure 4.4	Effect of oral administration of Pomegranate juice on feed intake in hypercholesterolemic rats.....	55
Figure 4.5	Effect of oral administration of Pomegranate juice on feed efficiency ratio (FER) in hypercholesterolemic rats.....	56
Figure 4.6	Effect of Pomegranate juice on relative weight of liver of hypercholesterolemic rats.....	59
Figure 4.7	Effect of Pomegranate juice on relative weight of heart of hypercholesterolemic rats.....	60
Figure 4.8	Effect of oral administration of Pomegranate juice on serum total cholesterol (TC) in hypercholesterolemic rats.....	63

Figure 4.9	Effect of oral administration of Pomegranate juice on serum triglycerides (TG) in hypercholesterolemic rats.....	64
Figure 4.10	Effect of oral administration of Pomegranate juice on serum levels of high density lipoprotein cholesterol (HDL-c) in hypercholesterolemic rats.....	68
Figure 4.11	Effect of oral administration of Pomegranate juice on serum levels of low density lipoprotein cholesterol (LDL-c) in hypercholesterolemic rats.....	69
Figure 4.12	Effect of oral administration of Pomegranate juice on serum levels of very low density lipoprotein cholesterol (VLDL-c) in hypercholesterolemic rats.....	70
Figure 4.13	Effect of oral administration of Pomegranate juice on serum levels of Aspartate aminotransferases (AST) in hypercholesterolemic rats.....	73
Figure 4.14	Effect of oral administration of Pomegranate juice on serum levels of Alanine aminotransferases (ALT) in hypercholesterolemic rats.....	74
Figure 4.15	Effect of oral administration of Pomegranate juice on liver homogenates levels of catalase (CAT) in hypercholesterolemic rats.....	77
Figure 4.16	Effect of oral administration of Pomegranate juice on liver homogenates levels of superoxide dismutase (SOD) in hypercholesterolemic rats.....	78
Figure 4.17	Effect of oral administration of Pomegranate juice on liver homogenates levels of glutathione peroxidase (GPx) in hypercholesterolemic rats.....	79
Figure 4.18	Section in the liver of a normal rat (negative control)..... (a-b)	82
Figure 4.19	Section in the liver of hypercholesterolemic rat (positive control).....	83
Figure 4.20	Section in the liver of hypercholesterolemic rat (positive control)..... (a-b)	84
Figure 4.21	Section in the liver of hypercholesterolemic rats after treatment with 1 ml/ kg b. wt., Pomegranate juice.....	85

Figure 4.22 (a-b)	Section in the liver of hypercholesterolemic rat after treatment with 3 ml/kg b. wt., Pomegranate juice.....	86
Figure 4.23	Section in the liver of hypercholesterolemic rat after treatment with 5 ml/kg b. wt., Pomegranate juice.....	87
Figure 4.24 (a-b)	Section of heart of normal rats (negative control).....	89
Figure 4.25 (a-b)	Section from rat heart of hypercholesterolemic rat (positive control).....	90
Figure 4.26 (a-b)	Section from rat heart of hypercholesterolemic rat after treated with 1 ml/kg b. wt., Pomegranate juice.....	91
Figure 4.27 (a-b)	Section in cardiac muscles of hypercholesterolemic rat after treatment with 3 ml/kg b. wt., Pomegranate juices.....	92
Figure 4.28 (a-b)	Section in cardiac wall of hypercholesterolemic rat after treated with 5ml/kg b. wt., Pomegranate juice.....	93

## LIST OF TABLES

<b>Table</b>		<b>Page number</b>
Table 4.1	Total polyphenols as gallic acid equivalents (GAEs), of Pomegranate juice.....	47
Table 4.2	Effect of oral administration of Pomegranate juice on initial body weight, final body weight and body weight gain % (BWG %) in hypercholesterolemic rats.....	49
Table 4.3	Effect of oral administration of Pomegranate juice on feed intake and feed efficiency ratio (FER) in hypercholesterolemic rats.....	54
Table 4.4	Effect of oral administration of Pomegranate juice on organs relative weight in hypercholesterolemic rats.....	58
Table 4.5	Effect of oral administration of Pomegranate juice on the serum level of total cholesterol (TC) and triglycerides (TG) in hypercholesterolemic rats.....	62
Table 4.6	Effect of oral administration of Pomegranate juice on the serum levels of lipoprotein fractions in hypercholesterolemic rats.....	67
Table 4.7	Effect of oral administration of Pomegranate juice on serum levels of liver function enzymes in hypercholesterolemic rats.	72
Table 4.8	Effect of oral administration of Pomegranate juice on liver homogenates levels of catalase (CAT), glutathione peroxidase (GPx) and superoxide dismutase (SOD) enzymes in hypercholesterolemic rats.....	76



## LIST OF ABBREVIATION

AHA	American Heart Association
ALP	Alkaline phosphatase
ALT	Alanine transaminase
ANOVA	Analysis of Variance
AST	Aspartate transaminase
b. wt.	Body weight
BDL	Bile Duct Ligation
BWG %	Body Weight Gain percent
CAT	Catalase
CCl <sub>4</sub>	Carbon tetrachloride
CEH	Cholesterol Ester Hydrolase
CES	Cholesterol Ester Synthetase
CHD	Coronary Heart Disease
cm	Centimeter
Con +ve	Control Positive
Con -ve	Control Negative
Cu Zn-SOD	Copper Zinc Superoxide Dismutase
CV	Central Vein
CVD	Cardiovascular Disease

DGAT1	Diacylglycerol acyltransferase 1
DNA	Deoxyribonucleic Acid
DPPH	1,1-Diphenyl-2-Picryl Hydrazyl
EA	Ellagic Acid
ET	Ellagitannin
Fe-NTA	Ferric Nitrilotriacetate
FER	Feed Efficiency Ratio
FH	Familial Hypercholesterolemia
FI	Feed Intake
g	Grams
g/l	Gram per Liter
GAEs	Gallic Acid Equivalents
GPx	Glutathione Peroxidase
GR	Glutathione Reductase
GSH	Reduced Glutathione
GSSG	Oxidized Glutathione Disulfide
GST	Glutathione Transferases
GT	Gallotannin
H & E	Hematoxylin and Eosin
H <sup>+</sup>	Hydrogen Ions
H <sub>2</sub> O <sub>2</sub>	Hydrogen Peroxide
HCL	Hydrogen Acid
HDL-c	High Density Lipoprotein Cholesterol

HFD	High Fat Diet
IHD	Ischemic Heart Disease
IMT	Intima-Media Thickness
Kg	Kilogram
LDL-c	Low Density Lipoprotein Cholesterol
LSD	Least Significant Difference
MDA	Malondialdehyde
MEPP	Methanol Extract of Pomegranate Peel
mg	Milligrams
mg/dL	Milligrams per deciliter
Mg/kg	Milligrams per Kilogram
Mg/kg <sup>-1</sup>	Milligrams per 1Kilogram of air
min	Minute
ml	Milliliters
Mm <sup>-1</sup>	Millimolar (concentration), i.e. 10 <sup>-3</sup> moles per liter
MM-LDL	Minimally Modified Low-Density Lipoprotein
mmol/L	Millimoles per liter
Mn-SOD	Manganese Superoxide Dismutase
n-3	Omega 3 fatty acids
NADP	Nicotinamide adenine dinucleotide phosphate
NADPH	Reduced nicotinamide adenine dinucleotide phosphate
nm	Nanometer
nmol	Nanomole
NO	Nitric Oxide

NTB	Nitro Tetrazolium Blue
O <sub>2</sub>	Oxygen
ox-LDL	Oxidized Low-Density Lipoprotein
P	Probability Values
P-CAD	Premature coronary artery disease
PFE	Pomegranate Fruit Extract
PH	Hydrogen Ion Concentration
PON1	paraoxonase 1
PPE	Pomegranate Peel Extract
ppm	Parts per million
PUFA	Polyunsaturated Fatty Acid
ROS	Reactive Oxygen Species
rpm	Revolution per minutes
SD	Standard Deviation
SFA	Saturated Fatty Acid
SOD	Superoxide Dismutase
SPSS	Statistical Package for Social Sciences
SR-A	Scavenger receptor A
TAS	Total Antioxidant Status
TBARS	Thiobarbituric acid reactive substances
TC	Total Cholesterol
TG	Triglycerides
U	Unit
VLDL-c	Very Low Density Lipoprotein Cholesterol

WHO	World Health Organization
$\mu\text{M}$	Micromolar (concentration), i.e. $10^{-6}$ moles per liter
$\mu\text{mol}$	Micromoles

# **CHAPTER I**

## **INTRODUCTION**

## **Chapter I**

### **Introduction**

Hypercholesterolemia has been well known as a proven risk factor for cardiovascular disease (CVD) (Wang *et al.*, 2011). The Saudi Arabia Ministry of Health reported that in 2010, CVD are the second causes of death with 5,239 deaths (17.3% of the total number of deaths 30,289) (Health Statistical, 2010). It is estimated that by the year 2030 the death rates from CVD will increase and will remain as leading cause of death in the world (WHO, 2008). Hypercholesterolemia is generally, associated with an increase in plasma concentrations of low density lipoprotein (LDL-c) (bad cholesterol) and very low density lipoprotein (VLDL-c) and / or a decrease in high density lipoprotein cholesterol (HDL-c) (good cholesterol). Modification of oxidation of LDL-c is thought to play a key role during early atherogenesis i.e. formation of atheroma inside the walls of blood vessels that finally lead to arteriosclerosis (Kumar *et al.*, 2008a). Because of an increased resistance of LDL-c to oxidation after treatment with various synthetic pharmaceutical drugs (Breugnot *et al.*, 1992; Pentikainen *et al.*, 1995), there is a great need to identify natural food products that can offer antioxidant protection against LDL-c oxidation.

Oxidative stress is a state in which oxidation exceeds the antioxidant systems in the body. Oxidative stress arises from an imbalance between the production of reactive oxygen species (ROS) and the body's antioxidant defenses against them, which intensifies cellular damage. The antioxidant defenses enable the body system to remove ROS, restore the prevailing reducing environment and repair the tissue damage (Halliwell and Gutteridge, 1999). Oxidative stress plays an important role in the etiology and pathogenesis of many chronic diseases such as atherosclerosis, hypertension diabetes mellitus, and cancers (Reuter *et al.*, 2010; Krajcovicova-Kudlackova, *et al.*, 2012).

Dietary intake of antioxidants can inhibit or delay the oxidation of susceptible cellular substrates so prevent oxidative stress. Therefore, it is important to enrich our diet with antioxidants to protect against many chronic diseases. Antioxidants also play an important role in food quality preservation due to their ability to prevent oxidative deterioration of lipids (Erukainure *et al.*, 2012). Antioxidants are important for health maintenance based on their modulation of the oxidation processes in the body (Lee *et al.*, 2002). Therefore, the search for cheap and abundant sources of natural antioxidants is attracting worldwide interest.

Consumption of fresh fruits and vegetables to improve human health has been attributed mainly to their high contents of beneficial phytochemicals and other micronutrients (Opara and Al-Ani, 2010). These phytochemicals mainly phenolic compounds (such as flavonoids, phenolic acids, diterpenes, saponins and tannins) have received much attention for their high antioxidative activity by scavenging free radicals



which cause oxidative stress that can lead to cellular damage and many degenerative disorders (Lampe, 1999; Boyer and Liu, 2004).

The edible part of Pomegranate fruit represents 52% of total fruit weight, comprising 78% juice and 22% seeds. Fresh Pomegranate juice is rich in vitamin C (El-Nemr *et al.*, 1990), and polyphenolic compounds such as anthocyanins, punicalagin, ellagic and gallic acid (Seeram *et al.*, 2005a; Lansky, 2006). Pomegranate fruit is widely considered as a healthy fruit due to its biological actions, most of these effects were attributed to its high phenolic content (Lansky and Newman, 2007). Previous studies on polyphenols of Pomegranate have been shown that these compounds are linked to the prevention of cardiovascular diseases, cancers and neurological damage in humans (Aviram *et al.*, 2002; Kuskoski *et al.*, 2004; Lansky and Newman, 2007). Flavonols and anthocyanins showed anti-carcinogenic, antimicrobial (Opara *et al.*, 2009), anti-inflammatory and antioxidant activities (Lansky and Newman, 2007). On the other hand, the phenyl propanoids as chlorogenic, caffeic and coumaric acids might be responsible of the inhibition of tumor initiation and development in rats as reported by Huang *et al.* (2005).

Several studies on Pomegranate extracts and its active constituents revealed that they have an antioxidant activity by scavenging free radicals, decreasing macrophage oxidative stress and preventing lipid peroxidation in animals as well as increasing plasma antioxidant capacity in elderly humans (Guo *et al.*, 2008). Studies in rats and mice confirm the antioxidant property of a Pomegranate by-product extract made from the whole fruit minus the juice, showed a 19 % reduction in oxidative stress in mouse

peritoneal macrophages, 42 % decrease in cellular lipid peroxides content, and 53% increase in reduced glutathione levels (Rosenblat *et al.*, 2006).

The present study was designed to investigate the effect of oral administration of Pomegranate juice on hypercholesterolemic rats.

### **1.2 Aim of the Study:**

The present study was performed to investigate the effect of oral administration of Pomegranate juice at three dosage levels on hypercholesterolemic rats after 4 weeks of treatment. The following parameters were tested:

- § Chemical estimation of Gallic acid equivalents (polyphenolic compound) concentration in Pomegranate juice.
- § Feed intake, body weight gain percent and feed efficiency ratio.
- § Relative organs weight of liver and heart.
- § Serum levels of total cholesterol (TC), triglycerides (TG), LDL-c, VLDL-c, HDL-c and liver enzymes (AST and ALT).
- § Activities of antioxidant enzymes [catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GPx)].
- § Histopathological examination of liver and heart of hypercholesterolemic rats orally given Pomegranate juice.

### **1.3 Objectives of the Study:**

1. Assay of chemical composition of total polyphenols (Gallic acid equivalents) in Pomegranate juice.
2. Assay of the serum levels of total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL-c), high density lipoprotein (HDL-c), and activities of liver enzymes (AST and ALT) at the end of the intervention period.
3. Assay of activities of antioxidant enzymes catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GPx) at the end of the intervention period.
4. Histopathological examination of liver and heart at the end of the intervention period.

## **CHAPTER II**


### **REVIEW OF LITERATURE**

## Chapter II

### Review of Literature

#### 2.1 Cholesterol:

Cholesterol is a sterol, a sort of fats, and its chemical structural formula is shown in Figure (2.1). It is one of the three major classes of lipids which all animal cells utilize to construct their membranes. It is also a precursor of steroid hormones, bile acids and vitamin D, which can be manufactured by all animal cells (Durrington, 2003; Gaziano and Gaziano, 2012).



**Figure 2.1 Chemical structural formula of Cholesterol (Durrington, 2003).**

Cholesterol is essentially insoluble in water; it is transported in blood and in protein particles (Berg *et al.*, 2007). The American Heart Association (AHA) describes the existence of two types of cholesterol :- (1) high density lipoproteins (HDL-c) which is considered good cholesterol, because it has the ability to carry excess cholesterol back to the liver for recycling, and (2) low density lipoproteins (LDL-c) which is the major carrier of cholesterol in humans. Low density lipoprotein (LDL-c), bad cholesterol, is harmful when its concentration is elevated in the blood. The ratio between these two types of cholesterol LDL/ HDL is defined an atherogenic index which is an important predictor of heart disease and atherosclerosis. The normal level cholesterol that should be found in the blood varies between 140 and 200 mg per deciliter (mg/dL). Elevated blood total cholesterol (hypercholesterolemia) occurs when its concentration become higher than 240 (mg/dL) (Schaefer, 2010; AHA, 2011).


### **2.1.1 Hypercholesterolemia:**

Hypercholesterolemia is the presence of high level of total cholesterol in the blood. It is the form of "hyperlipidemia" (elevated levels of lipids in the blood) and "hyperlipoproteinemia"(elevated levels of lipoproteins in the blood). Hypercholesterolemia may lead to accumulation, oxidation and modification of lipids in the vascular endothelium leading to endothelial dysfunction, chronic inflammation and cardiovascular diseases (CVD) as mentioned by Insull (2009).

Epidemiological studies have shown that higher concentrations of LDL-c can be correlated to an increase risk of CVD and development of atherosclerosis (Catapano,

2009). The pathogenesis of atherosclerosis is initiated by elevated levels of LDL-c that accumulate in the arterial intima and are subject to oxidation by free radicals i.e. Reactive oxygen species (ROS) (Saini *et al.*, 2004; Gropper *et al.*, 2009). When the amount of ROS rises above normal levels, which has been associated with many chronic disease states including hypercholesterolemia and atherosclerosis, the antioxidant system of the body is overwhelmed resulting in the oxidation of particles such as proteins and lipids (Manach *et al.*, 2005; Vincent and Taylor, 2006).

The oxidation of the lipid particle LDL-c is known to increase its atherogenicity since oxidized-low-density lipoprotein (ox-LDL) is recognized by macrophages and taken up via scavenger receptors. The macrophages are then thought to become foam cells which form plaque (atheroma) on the wall of arteries, and thus a case of arteriosclerosis developed (Stocker and Keane, 2004) (Figure 2.2). Therefore, the oxidative modification of LDL-c associated with lipids is directly involved in the initiation process of atherosclerosis (Albertini *et al.*, 2002).



**Figure 2.2 The development of atherosclerosis (Singh *et al.*, 2005).**

LDL, Low-density lipoprotein; MM-LDL, minimally modified low-density lipoprotein; ox-LDL, oxidized-low-density lipoprotein; ROS, reactive oxygen species; SR-A, scavenger receptor A.



### **2.1.1.1 Signs and Symptoms of Hypercholesterolemia:**

Hypercholesterolemia is asymptomatic, long standing elevation of serum total cholesterol can lead to atherosclerosis (Bhatnagar *et al.*, 2008). Over a period of decades, chronically elevated serum total cholesterol contributes to formation of atheromatous plaques in the arteries. These processes cause progressive stenosis (narrowing) or even complete occlusion (blockage) of the involved arteries. Blood supply to the tissues and organs served by these stenotic or occluded arteries gradually diminishes until organ function becomes impaired. It is at this point tissue ischemia (restriction in blood supply) may manifest as specific symptoms. For example, temporary ischemia of the brain (commonly referred to as a transient ischemic attack) may manifest as temporary loss of vision, dizziness and impairment of balance, aphasia (difficulty speaking), paresis (weakness) and paresthesia (numbness or tingling), usually on one side of the body. Insufficient blood supply to the heart may manifest as chest pain, and ischemia of the eye may manifest as transient visual loss in one eye. Insufficient blood supply to the legs may manifest as limb pain when walking, while in the intestines it may present as abdominal pain after eating a meal (Grundy *et al.*, 1998; Durrington, 2003).

Some types of hypercholesterolemia lead to specific physical findings. For example, familial hypercholesterolemia (FH) (Type IIa hyperlipoproteinemia) may be associated with xanthelasma palpebrarum (yellowish patches underneath the skin around the eyelids)(Shields and Shields, 2008), arcus senilis (white or gray discoloration of the peripheral cornea)( Zech and Hoeg, 2008).

Hypercholesterolemia is typically asymptomatic; certain physical changes may occur, including the appearance of cholesterol-rich skin deposits, called xanthomas. These can occur on the eyelids (xanthelasma), or can develop on the elbows, knees, buttocks, tendons, and around the cornea of the eye (Zuliani and Renato, 2003; James and Berger, 2011).

#### **2.1.1.2 Causes of Hypercholesterolemia:**

Hypercholesterolemia is typically due to a combination of environmental and genetic factors (Bhatnagar *et al.*, 2008). Environmental factors include: Elements such as diet, exercise, and smoking all affect levels of cholesterol as well as age, gender, and co-occurring diabetes and obesity (Gaziano *et al.*, 2007). Genetic contributions are usually due to the additive effects of multiple genes, however occasionally may be due to a single gene defect such as in the case of familial hypercholesterolemia (Bhatnagar *et al.*, 2008).

A strong association was found between hypercholesterolemia and number of secondary causes exist including: diabetes mellitus type 2, obesity, alcohol drinking, monoclonal gammopathy, dialysis, nephrotic syndrome, obstructive jaundice, hypothyroidism, Cushing's syndrome, anorexia nervosa and some medications (thiazide diuretics, cephalosporin, glucocorticoids, beta blockers, retinoic acid) (Zuliani and Renato, 2003; Bhatnagar *et al.*, 2008).

Diet has an important effect on blood cholesterol but the size of this effect varies substantially between individuals (Howell *et al.*,1997).Approximately 50% of dietary cholesterol is absorbed in the intestine but inter-individual variations in the efficiency of uptake, and the effect of other dietary components such as plant sterols and fiber content affect absorption (Lichtenstein,1990). Moreover, when dietary cholesterol intake goes down, production (principally by the liver) (Berg *et al.*, 2007) typically increases, though not always with complete compensation, so that reductions in blood cholesterol can be modest. Reductions in fat intake, particularly saturated fats, also reduce blood cholesterol (Sacks and Katan, 2002). If a proper regimen of a healthier diet, increase in exercise and addition of medication is implemented cholesterol levels can be reduced especially for heterozygous hypercholesterolemic individuals (Gaziano *et al.*, 2007; Ito *et al.*, 2011).

Gender difference currently plays an important role in the etiology of hyperlipidemic induced disorders including CVD. For instance, men are more susceptible to coronary heart disease than age-matched women. However, postmenopausal women have an equal chance of CVD with men (Schwab *et al.*, 2011).

Genetic variations are one factor that responsible for hypercholesterolemia, such as in FH where there are one or more genetic mutations happens for example, the LDL-c receptor (Sibley and Stone, 2006). Familial hypercholesterolemia (FH) is one of the most common genetic disorders and it provides the best evidence on the etiologic role of LDL cholesterol for arteriosclerosis development (Araujo *et al.*, 2011). Familial hypercholesterolemia (FH) is caused by an autosomal dominant mutation of the LDL-c

receptor gene, resulting in high levels of LDL-c and premature coronary artery disease (P-CAD) (Yudi *et al.*, 2012).

### **2.1.2 Antioxidant Enzymes Related to Hypercholesterolemia:**


The preventative antioxidants include the metal chelating proteins and the endogenous antioxidant enzymes catalase (CAT), glutathione peroxidase (GPx) and superoxide dismutase (SOD). The concentrations and locations of these antioxidants are highly regulated because their main function is to suppress the formation of free radicals to prevent cellular damage or promote cell survival (Willcox *et al.*, 2004).

Catalase (CAT) is an antioxidant enzyme which acts to detoxify hydrogen peroxide ( $H_2O_2$ ) by converting it into water and oxygen (Oh *et al.*, 2007) (Figure 2.3). It has one of the highest turnover rates of all enzymes and can convert millions of  $H_2O_2$  molecules per second (Sendur *et al.*, 2009). Depressed CAT is associated with an increased risk of chronic diseases associated with oxidative stress such as atherosclerosis, diabetes, neurodegenerative diseases and postmenopausal osteoporosis (Oh *et al.*, 2007).

Glutathione peroxidase (GPx) is an antioxidant enzyme associated with selenium, which is required for its optimal function (Schwedhelm *et al.*, 2003). It is found in the plasma and the cytosolic or membrane compartment of tissues (Willcox *et al.*, 2004). It catalyzes the conversion of  $H_2O_2$  into water and oxygen, using reduced

glutathione (GSH) as a substrate which is oxidized to glutathione disulfide (GSSG) in the process (Figure 2.3).

Superoxide dismutase (SOD) catalyzes the dismutation of  $O_2^{\bullet-}$  to oxygen and  $H_2O_2$ , the latter of which is subsequently neutralized by CAT or GPx into water and oxygen (Figure 2.3). Superoxide dismutase (SOD) exists in three isoforms: manganese (Mn-SOD), copper zinc (Cu Zn-SOD) and extracellular. Superoxide dismutase (SOD) is localized in the intracellular space of tissues and is filtered through the kidney before being reabsorbed and catabolized within the proximal tubules (Schwedhelm *et al.*, 2003). Free radicals which are not effectively suppressed by these preventative antioxidants initiate peroxidative chain reactions which must then be terminated by the chain-breaking, radical-scavenging antioxidants (Willcox *et al.*, 2004).



**Figure 2.3 Schematic of formation of reactive oxygen species formation, including points of antioxidant enzyme action (Oh *et al.*, 2007).**

Several studies have shown that intake of high amounts of saturated fatty acids (SFAs) may increase oxidative stress by increasing lipid peroxidation and decreasing antioxidant enzymes (Diniz *et al.*, 2004). This may be due to the hypercholesterolemic effect of SFAs, whereby elevated plasma LDL-c levels can lead to increased retention and oxidation of LDL-c in the arterial wall (Stocker and Keaney, 2004). Moreover, hypercholesterolemia is associated with increased superoxide production and nitric-oxide (NO) inactivation (Landmesser *et al.*, 2000). Due to their high degree of saturation, polyunsaturated fatty acids (PUFAs) are highly susceptible to damaging, free radical-initiated lipid peroxidation. Consequently, PUFAs also tend to be positively associated with oxidative stress (Kris-Etherton *et al.*, 2004).

Diniz *et al.* (2004) found that a high-SFA diet (28.8% total fat, 82% SFAs, 8% PUFAs; P: S ratio ~0.10) increased hydroperoxide concentrations and decreased glutathione peroxidase activity in cardiac tissue of male Wistar rats when compared to the control rats (3.8% total fat, 49% SFAs, 39% PUFAs; P: S ratio ~0.79).

## **2.2 Pomegranate:**

Nowadays, it is widely accepted that the beneficial health effects of fruits and vegetables in the prevention of disease are due to the bioactive compounds they contain (Galaverna *et al.*, 2008). The presence of significant amounts of bioactive compounds such as phenolic acids, flavonoids, and tannins in Pomegranate fruits assures them considerable nutritional value (Aviram *et al.*, 2000).

The Pomegranate fruit has an ancient history and is mentioned in many Holy Scriptures such as the Torah, the Bible, and the Holy Quran (Langley, 2000; Longtin, 2003). The tree is native to the region of Persia and the Himalayan ranges of India and has been cultivated in Iran, Afghanistan, Pakistan, North India, Armenia, Azerbaijan, Georgia, and the Mediterranean region for several millennia (Jurenka, 2008). Saudi Arabia also is a famous on Pomegranate (El-Rashedy *et al.*, 2011). Pomegranate has been used in various regions and folk or traditional medical systems as a food supplement or a medicine because of its enormous compounds with lots of activities and without toxicity (Lansky and Newman, 2007). Sculptured representations of the fruit are found on the ancient monuments of Egypt and the Assyrian ruins (Jurenka, 2008).

The Pomegranate fruit could be considered a functional food because it has valuable compounds in different parts of the fruit that display functional and medicinal effects. These compounds can act as antioxidant (Cam *et al.*, 2009), as antitumor (Hamad and Al-Momene, 2009) as antihepatotoxic agents (Celik *et al.*, 2009), and improve cardiovascular health (Davidson *et al.*, 2009). They have been reported to have antimicrobial (Duman *et al.*, 2009), anti-inflammatory (Lee *et al.*, 2010), antiviral (Haidari *et al.*, 2009) and antidiabetic (Xu *et al.*, 2009) properties. They can improve oral (Di Silvestro *et al.*, 2009) and skin (Aslam *et al.*, 2006) health. They help to prevent Alzheimer's disease (Singh *et al.*, 2008), improve sperm quality (Turk *et al.*, 2008) and erectile dysfunction in male patients (Forest *et al.*, 2007).

### **2.2.1 Nutritional Value of Pomegranate:**

The Pomegranate fruit has valuable compounds in different parts of the fruit. These parts can be divided into several anatomical origins: peel, seeds, and arils. An important product obtained from Pomegranate fruit is the juice that can be obtained from arils or from whole fruit. The chemical composition of Pomegranate fruits differs according to the cultivar, growing region, climate, maturity, cultivation practice, and storage conditions (Poyrazoglu *et al.*, 2002; Barzegar *et al.*, 2004; Fadavi *et al.*, 2005). Significant variations in organic acids, phenolic compounds, sugars, water-soluble vitamins, and minerals of Pomegranates have been reported over the years by various researchers (Aviram *et al.*, 2000; Mirdehghan and Rahemi, 2007; Cam *et al.*, 2009; Davidson *et al.*, 2009; Tezcan *et al.*, 2009). About 50% of the total fruit weight corresponds to the peel, which is an important source of bioactive compounds such as phenolic, flavonoids, ellagitannins (ETs), and proanthocyanidin compounds (Li *et al.*, 2006), minerals, mainly potassium, nitrogen, calcium, phosphorus, magnesium, and sodium (Mirdehghan and Rahemi, 2007), and complex polysaccharides (Jahfar *et al.*, 2003).

The edible part of Pomegranate fruit (50%) consists of 40% arils and 10% seeds. Arils contain 85% water, 10% total sugars, mainly fructose and glucose, and 1.5% pectin, organic acid such as ascorbic acid, citric acid and malic acid as well as bioactive compounds such as phenolic compounds and flavonoids, principally anthocyanins (Aviram *et al.*, 2000; Tezcan *et al.*, 2009).



The seeds are a rich source of total lipids; Pomegranate seed oil comprises 12% to 20% of total seed weight. The oil is characterized by a high content of polyunsaturated (n-3) fatty acids such as linolenic, linoleic, and other lipids such as punicic acid, oleic acid, stearic acid, and palmitic acid (Ozgul-Yucel, 2005; Fadavi *et al.*, 2006). The seeds also contain protein, crude fibers, vitamins, minerals, pectin, sugars, polyphenols, isoflavones (mainly genistein), the phytoestrogen coumestrol, and the sex steroid estrone (El-Nemr *et al.*, 1990; Syed *et al.*, 2007).

Pomegranate juice was reported to be composed of 85.4% water, 10.6% total sugars (fructose and glucose are present in similar quantities), 1.4% pectin, content in Pomegranate juice varies within the limits of 0.2–1.0%, depending on variety, and includes mainly anthocyanins (such as cyanidin-3-glucoside, cyanidin-3,5-diglucoside, and delphinidin-3-glucoside), catechins. Several studies reported that minor compounds include calcium is 50% of its ash content, and the principal amino acids are glutamic and aspartic acids and organic acids, indoleamines, sterols, triterpenoids and  $\alpha$  tocopherol (Poyrazoglu *et al.*, 2002; Ignarro *et al.*, 2006; Lansky and Newman, 2007; Heber *et al.*, 2007; Mousavinejad *et al.*, 2009; Jaiswal *et al.*, 2010; Krueger, 2012). Minerals in the Pomegranate juice and seed include iron, relatively prevalent, but not in so high concentrations as in watermelon, and calcium, chlorine, copper, potassium, magnesium, manganese, sodium, selenium and zinc (Waheed *et al.*, 2004). In addition, Pomegranate juice contains 21 mg/ 100g vitamin C (Esmailzadeh *et al.*, 2004).

Pomegranate juice contains approximately 5 mmol/L of total polyphenols in comparison to other fruit juices which contain approximately 1.3 to 4.0 mmol/L of total polyphenols (Seeram *et al.*, 2006). Ellagitannins (ETs) and anthocyanins are the principal antioxidant polyphenols in Pomegranate juice (Gil *et al.*, 2000). Anthocyanins, which are the water-soluble pigments that give Pomegranate juice its bright red color, are found in the arils of the Pomegranate (Seeram *et al.*, 2006). The ETs are present in the peel, the membranes and piths of the fruit and account for approximately 92 % of the total antioxidant activity of Pomegranate juice (Seeram *et al.*, 2006; Gil *et al.*, 2000).

The major ETs present in the whole fruit are punicalagins, which can be hydrolyzed to ellagic acid (EA) and other smaller polyphenols *in vivo* (Seeram *et al.*, 2004b). Commercial Pomegranate juice obtained by pressing whole Pomegranate fruit and its peels contains significant amounts of water soluble compounds, including punicalagins. However punicalagin levels vary widely in Pomegranate juice and can range from as low as 0.017 to 1.5 g/L of juice depending on the fruit cultivar as well as the processing and storage conditions (Gil *et al.*, 2000; Seeram *et al.*, 2004a).


#### **2.2.1.1 Phenolic Compounds:**

One of the main compounds responsible for most of the functional properties of many foods, among them Pomegranate fruit, are phenolic compounds in any of their forms (Viuda-Martos *et al.*, 2011). Natural polyphenols can range from simple molecules (phenolic acids, phenylpropanoids and flavonoids) to highly polymerized compounds (lignins, melanins and tannins), with flavonoids representing the most

common and widely distributed subgroup (Soobrattee *et al.*, 2005). Chemically, phenolic acids can be defined as substances that possess an aromatic ring bound to one or more hydrogenated substituents, including their functional derivatives (Marin *et al.*, 2002).

Flavonoids are low-molecular weight compounds consisting of 15 carbon atoms, arranged in a C<sub>6</sub>-C<sub>3</sub>-C<sub>6</sub> configuration. Essentially, the structure consists of 2 aromatic rings joined by a 3-carbon bridge, usually in the form of a heterocyclic ring (Balasundram *et al.*, 2006).


Anthocyanins are the largest and most important group of flavonoids present in Pomegranate arils, which are used to obtain the juice. These pigments give the fruit and juice its red color (Afaq *et al.*, 2005). There is a great variety of anthocyanins present in Pomegranate juice (Figure 2.4), principally cyanidin-3-O-glucoside, cyanidin-3, 5-di-O-glucoside, delphinidin-3-O-glucoside, delphinidin-3, 5-di-O-glucoside, pelargonidin-3-O-glucoside, and pelargonidin-3,5-di-O-glucoside (Lansky and Newman, 2007; Jaiswal *et al.*, 2010). The main differences between them are the number of hydroxylated groups, the nature and the number of bonded sugars to their structure, the aliphatic or aromatic carboxylates bonded to the sugar in the molecule, and the position of these bonds (Kong *et al.*, 2003).



**Figure 2.4 Principal anthocyanins present in Pomegranate juice (Viuda-Martos *et al.*, 2011).**

1: cyanidin-3-O-glucoside; 2: cyanidin-3, 5-di-O-glucoside; 3: delphinidin-3-O-glucoside; 4: delphinidin-3,5-di-O-glucoside; 5: pelargonidin-3-O-glucoside; 6: pelargonidin-3,5-di-O-glucoside.

The phenolic acids present in Pomegranate juice (Figure 2.5) can be divided into 2 groups: (1) hydroxybenzoic acids, mainly Gallic acid and EA (Amakura *et al.*, 2000); and (2) hydroxycinnamic acids, principally caffeic acid, chlorogenic acid, and p-coumaric acid (Poyrazoglu *et al.*, 2002).




**Figure 2.5 Principal phenolic acids present in Pomegranate juice (Viuda-Martos *et al.*, 2011).**

1: p-coumaric acid; 2: chlorogenic acid; 3: caffeic acid; 4: EA; 5: gallic acid.

### **2.2.1.2 Tannins:**

Tannins are high-molecular-weight plant polyphenols divided into 3 chemically and biologically distinct groups: condensed tannins or proanthocyanidins (as found in tea, grapes, cranberries, and so on) and hydrolyzable tannins or ETs (as in raspberries, strawberries, and so on) as well as gallotannins (GTs) (Seeram *et al.*, 2005b). Pomegranate peel is rich in hydrolyzable tannins (Figure 2.6), mainly punicalin, pedunculagin, and punicalagin (Seeram *et al.*, 2005a). Tannins differ from proanthocyanidins in their chemical structures. ETs are esters of hexahydroxydiphenic acid and a polyol, usually glucose or quinic acid (Clifford and Scalbert, 2000). In addition to ETs, Pomegranate peel contains hydroxybenzoic acids such as gallagic, EA, and ellagic acid glycosides (Amakura *et al.*, 2000); anthocyanidins are principally cyanidin, pelargonidin, and delphinidin (Noda *et al.*, 2002) and flavonoids such as kaempferol, luteolin, and quercetin (Van Elswijk *et al.*, 2004).



**Figure 2.6 Principal ellagitannins (ETs) present in Pomegranate peel (Viuda-Martos *et al.*, 2011).**

1: punicalin; 2: pedunculagin; 3: punicalagin.

### **2.3 Effect of Pomegranate on Blood Lipid:**

One of the major risk factors for the development of coronary heart disease (CHD) is dyslipidemia, which is mainly characterized by elevated levels of LDL-c and/or reduced HDL-c (Esmailzadeh and Azadbakht, 2008). Oxidation LDL-c is thought to contribute to atherosclerosis and CVD (Heinecke, 2006). *In vitro*, animal and human trials have examined the effects of various Pomegranate constituents on the prevention and attenuation of atherosclerosis and LDL-c oxidation (Aviram *et al.*, 2000; Fuhrman *et al.*, 2005; Ignarro *et al.*, 2006; Sezer *et al.*, 2007; Basu and Penugonda, 2009; Davidson *et al.*, 2009; Fuhrman *et al.*, 2010).

Aviram *et al.* (2000) reported that Pomegranate juice inhibited atherogenic modifications of LDL-c, including its retention, oxidation, and aggregation. The antiatherogenicity capability of Pomegranate juice is related to three components of atherosclerosis: plasma lipoproteins, arterial macrophages, and blood platelets. The potent antioxidative capacity of Pomegranate juice against lipid peroxidation may be the central link for the anti-atherogenic effects of Pomegranate juice on lipoproteins, macrophages, and platelets.

Sumner *et al.* (2005) examined whether daily consumption of Pomegranate juice for three months would affect myocardial perfusion (blood flow in the heart) in CHD and stress-induced ischemia (patients had undergone treadmill exercise or pharmacologic stress). The results showed that patients who consumed Pomegranate juice daily (240ml/day) for three months had a decrease in stress-induced ischemia



compared to the controls that had an increase in stress-induced ischemia. Also there was an average improvement of 17% in myocardial perfusion in the Pomegranate juice group and an average worsening of 18% in myocardial perfusion in the control group.

Esmailzadeh *et al.* (2006) investigated the effect of concentrated Pomegranate juice consumption (40 g) on lipid profiles of type II diabetic patients with hyperlipidemia (total cholesterol or triglycerides  $\geq$  200 mg/dL). At the end of assay eight weeks, the results showed that there were no significant changes in serum triacylglycerol and HDL-c concentrations. However, reductions were obtained in total cholesterol (TC) (5.43%), LDL-c (9.24%), TC / HDL -c ratio (7.27%), and LDL / HDL ratio (11.76%).

Fuhrman *et al.* (2005) reported that Pomegranate juice exerts a direct effect on macrophage cholesterol metabolism by reducing cellular uptake of ox-LDL and inhibiting cellular cholesterol biosynthesis. Both of these processes eventually lead to a reduction in macrophage cholesterol accumulation and foam cell formation and attenuation of atherosclerosis development.

Basu and Penugonda (2009) suggested that the principal mechanisms of action of Pomegranate juice is anti-atherogenic and may include the following: decreased plasma lipids, lipid peroxidation, oxidized- LDL-c uptake by macrophages, intima media thickness, atherosclerotic lesion areas, inflammation, angiotensin converting enzyme activity and decreased systolic blood pressure; on the other hand Pomegranate juice increased serum antioxidant capacity enhanced biological actions of NO, which event

led to favorable effect on the progression of atherosclerosis and the subsequent potential development of CHD.

Anoosh *et al.* (2010) studied the effect of Pomegranate juice on plasma LDL-c in hypercholesteolemic patients. In this investigation, patients were divided into three groups with twenty patients in each group. The treatments were including: Group one; using tabrizy variety of Pomegranate juice, Group two; black varieties of Pomegranate juice and Group three; a drug lovastatin (one of statins), for four weeks and then the authors compared the consumption of group one and two with group three. The results showed that there was no difference between group one and two with group three. As with the drug, the two groups (one and two) were effective in decreasing the level of LDL-c.

Rosenblat and Aviram (2011) demonstrated that consumption of fifty  $\mu\text{M}$  of Pomegranate juice is able to affects the triglyceride biosynthesis which could be attributed to a direct effect of Pomegranate juice on diacylglycerol acyltransferase 1(DGAT1) activity.

Hossin (2009) reported that supplementation of pomegranate peels powder and its extract to obese hypercholesteolemic male rats had a significant decreases on lipid metabolism , food consumption, body weight gain ratio and all tested lipid parameters except HDL-c compared to control positive group(hypercholesteolemic rats).

Chalfoun-Mounayar *et al.* (2012) demonstrated that pomegranate molasses or juice when added to the drinking water of mice (4 ml/L) during 11 weeks led to a significant decrease in weight curve compared to control animals; also triglycerides and peroxidation were decreased in the heart, lungs, and the liver, while SOD activity increased. In conclusion, Pomegranate molasses possesses a powerful antioxidant activity and a weight loss effect in mice.

#### **2.4 Effect of Pomegranate on Liver Function:**

Epidemiological studies suggested the existence of a close association between liver disease and the prevalence of metabolic disorders such as dyslipidemia, insulin resistance, and hyperglycemia (Must *et al.*, 1999). Although several lines of evidence suggested that hyperlipidemia may not play a causal role in liver injury, they may affect the severity of tissue damage (Jou *et al.*, 2008). Indeed, liver damage is more severe when there are multiple coincidental insults. For example, excess lipid accumulation in the form of triglycerides in the cytosol of hepatocytes, which per se does not appear to impair liver function, significantly increases the vulnerability of the liver to the deleterious effects of cytokines, oxidative agents, and viral infections, predisposing this organ to inflammation and advanced fibrosis (Farrell and Larter, 2006).

Although hypercholesterolemia is a prominent metabolic disorder and a major risk factor for coronary heart disease and atherosclerosis, its precise contribution to the progression of hepatic steatosis, inflammation, and fibrosis has been practically overlooked. In this regard, apart from epidemiological studies suggesting

hypercholesterolemia as an independent risk factor for liver disease, a study suggesting that hypercholesterolemia increases susceptibility to virus-induced immunopathological liver disease experimental studies in rodents and rabbits demonstrating an association between the intake of high cholesterol and high-fat diets (HFD) with liver steatosis and inflammation (Ludewing *et al.*, 2001; Pendino *et al.*, 2005; Tous *et al.*, 2005).

Lu *et al.* (2007); Prasad (2010) and Saki *et al.* (2011) studied the effect of hypercholesterolemia on serum levels of as alanine aminotransaminase (ALT), aspartate aminotransaminase (AST) and alkaline phosphatase (ALP). The results showed that a high cholesterol diet moderately elevated serum levels of ALT, AST and ALP in rats.

Toklu *et al.* (2007) assessed the effect of oral administration of Pomegranate peel extract (PPE) at 50 mg kg<sup>-1</sup> or saline to rats for twenty-eight days on liver fibrosis induced by bile duct ligation (BDL). The results showed that the elevation of AST and ALT were significantly decreased after treatment. This effect may be due to antioxidant and antifibrotic properties of PPE and also from potential therapeutic value in protecting the liver from fibrosis and oxidative injury.

Osman *et al.* (2012) investigated the antioxidant effect of Pomegranate peel and juice on diabetes mellitus induced by alloxan in female rats. Thirty two rats were allocated into four groups as follows: Group one; control without any treatment; Group two: diabetic animals injected with alloxan; Group three: diabetic peel group animals injected with alloxan and then fed on peel Pomegranate; Group four: diabetic juice group animals injected with alloxan and then gavage with Pomegranate juice, for four

weeks treatment. The results showed that AST and ALT were significantly increased in the diabetic group. After treatment with peel and juice, AST and ALT levels decreased and become near to the control levels, especially ALT value. Furthermore, levels of TC, TG, LDL-c and total lipids increased, while HDL decreased in diabetic group. Administration of peel and juice of Pomegranate prevented these changes.

Fyiad *et al.* (2012) studied the effect of Pomegranate juice on nucleic acids alterations and oxidative stress in rats with experimentally hepatitis. Results revealed that the pretreatment with Pomegranate juice (twenty ml/ kg<sup>-1</sup> b. wt., day<sup>-1</sup> for fourteen days) effectively hindered the adverse effect of D-Galactosamine / lipopolysaccharide and protect against hepatic damage via suppression of oxidative stress. Histopathological studies of the liver of different groups also support the protective effects exhibited by Pomegranate juice through restoring the normal hepatic architecture. These were also significant decreases in the serum level of diagnostic marker enzymes (AST, ALT and ALP) as compared to the alleviation of D-Galactosamine / lipopolysaccharide –induced hepatitis control group.

## **2.° Effect of Pomegranate on Antioxidant Enzymes:**

The antioxidant and sensory qualities of Pomegranates depend on several factors, such as cultivar, climatic conditions during fruit maturation and ripening and the part of the fruit used (Borochoy-Neori *et al.*, 2009). Thus, Singh *et al.* (2002) reported that a methanol extract of Pomegranate peel had much higher antioxidant capacity than that of

seeds, as demonstrated by using both  $\beta$ -carotene-linoleate and 1, 1-diphenyl-2-picrylhydrazyl( DPPH) model assays.

Tzulker *et al.* (2007) reported that the homogenate prepared from the whole Pomegranate fruit exhibited an approximately twenty-fold higher antioxidant activity than the level of that prepared from the aril juice.

The antioxidant activity of Pomegranate components has been the subject of many studies (Naveena *et al.*, 2008; Cam *et al.*, 2009; Mousavinejad *et al.*, 2009; Tezcan *et al.*, 2009), most conducted *in vitro* and *in vivo*. All these activities may be related to the diverse phenolic compounds present in Pomegranate, including punicalagin isomers, EA derivatives, and anthocyanins (delphinidin, cyaniding, pelargonidin 3- glucosides, and 3, 5-diglucosides). These compounds are known for their properties to scavenge free radicals and to inhibit lipid oxidation *in vitro* (Gil *et al.*, 2000; Noda *et al.*, 2002).

However, Tzulker *et al.* (2007) suggested that punicalagin originating from the peels is one of the major phytochemicals contributing to the total antioxidant capacity of Pomegranate juice, while anthocyanins play only a minor role in this activity. The action and mechanism of action set in motion by the antioxidant activity of these compounds are still not clearly understood, although it is a known fact that antioxidant mechanisms involved in biological matrixes are quite complex and several different factors may play a role (Cam *et al.*, 2009).

Aviram *et al.* (2004) conducted a study with nineteen patients suffering from carotid artery stenosis, patients were divided into two groups: Nine patients that did not consume Pomegranate juice served as a control group; Ten patients were included in the Pomegranate juice in a dose of 50 ml/day for one year as treated group. The results showed that there was an increased in common carotid intima-media thickness (IMT) by 9% during one year for the control group; Whereas, Pomegranate juice consumption resulted in a significant IMT reduction, by up to 30%, after one year. Furthermore, serum levels of antibodies against ox-LDL were decreased by 19%, and in parallel serum total antioxidant status (TAS) was increased by 130% after one year of Pomegranate juice consumption.

Madrigal-Carballo *et al.* (2009) suggested that Pomegranate polyphenolic molecules undergo redox reactions because phenolic hydroxyl groups readily donate hydrogen for reducing agents. Negi and Jayaprakasha (2003) have also reported a significant increase in the antioxidant reducing power of Pomegranate peel extracts with increases in concentration from 50 to 400 ppm. Reducing properties are generally associated with the presence of reducing agents (Pin-Der, 1998).

Gordon (1990) reported that the antioxidative action of reducing agents is based on the breaking of the free radical chain by the donation of a hydrogen atom. Reducing agents also react with certain precursors of peroxides, thus preventing peroxide formation (Naveena *et al.*, 2008). However, Amarowicz *et al.* (2004) suggested that the antioxidant activity of phenolic compounds is due to their ability to scavenge free radicals or chelate metal cations.

Gil *et al.* (2000) reported that Pomegranate juice possessed a three-folds higher antioxidant activity than that of red wine or green tea, and two-, six-, and eight-folds higher levels than those detected in grape/cranberry, grape fruit, and orange juices, respectively (Azadzoi *et al.*, 2005; Rosenblat and Aviram, 2006).

Guo *et al.* (2008) found that consumption of 250 mL Pomegranate pulp juice daily for four weeks by healthy elderly subjects resulted in increased plasma antioxidant capacity, while subjects consuming apple juice experienced no significant increase. In addition, subjects consuming the Pomegranate pulp juice exhibited significantly decreased plasma carbonyl content, a biomarker for oxidant/antioxidant barrier impairment in various inflammatory diseases.

Seeram *et al.* (2008) demonstrated that Pomegranate juice had the greatest antioxidant potency composite index among such beverages as apple juice, açaí juice, black cherry juice, blueberry juice, cranberry juice, grape juice, orange juice, red wines, and iced tea; and the antioxidant activity was at least 20% greater than any of the other beverages tested. Indeed, Aviram and Dornfeld (2001) reported that consumption of Pomegranate juice, which is rich in tannins; possess anti-atherosclerotic properties that could be related to its potent antioxidative characteristics.

Flavonoids also make a great contribution to the antioxidant activity of Pomegranate due to their effect on free radicals elimination (Wang *et al.*, 2006; Suo *et al.*, 2009). It seems that flavonoids from Pomegranate possess had a significant antiperoxidative activity. It was evidenced by that the concentrations of



malondialdehyde, hydroperoxides and conjugated dienes in the liver, heart and kidney were significantly reduced and the activities of the enzymes such as CAT, SOD, GPx, glutathione reductase (GR) and the concentration of glutathione in the tissue were significantly enhanced after the orally administered with total flavonoids from Pomegranate (Sudheesh and Vijayalakshmi, 2005).

A separate study on rats with carbon tetrachloride (CCl<sub>4</sub>) induced liver damage demonstrated that pretreatment with a Pomegranate peel extract enhanced or maintained the free radicals scavenging activity of the hepatic enzymes CAT, SOD, and peroxidase, and resulted in 54% reduction of lipid peroxidation values compared to control groups (Chidambara *et al.*, 2002).

Ajaikumar *et al.* (2005) studied the effect of consumption of 70% methanolic extract of *Punica granatum* fruit at 250 mg/kg and 500 mg/kg on rats that suffer from gastric ulceration. The results showed that SOD, CAT, GSH and GPx levels were increased and found more or less equal to the normal values. The tissue lipid peroxidation level was found to be decreased in treated groups of animals as compared to the control group. The authors concluded that gastroprotective activity of the extract may be due to its antioxidant mechanism.

Faria *et al.* (2007) investigated the antioxidant activity, which has been related to beneficial health properties of Pomegranate juice in male mice. For this purpose, mice ingested Pomegranate juice (or water in control group) during four weeks, after which damage to lipids; proteins and DNA were evaluated as oxidative cell biomarkers. Levels

of hepatic glutathione and the activities and expression of enzymes involved in its metabolism were determined. Catalase (CAT) and SOD activities were quantified as these enzymes have a crucial role in antioxidant defense. Protection against protein and DNA oxidation was found in Pomegranate juice group. There was also a significant decrease in all studied enzymatic activities (GPx, GST, GR, SOD and CAT) by Pomegranate juice treatment.

The effect of Pomegranate juice consumption on antioxidant activity of male healthy rats was studied by Turk *et al.* (2008). Twenty-eight healthy adult male Wistar rats were divided into four groups; each group containing seven rats. One mL distilled water, 0.25 mL Pomegranate juice plus 0.75 mL distilled water, 0.50 mL Pomegranate juice plus 0.50 mL distilled water and 1 mL Pomegranate juice were given daily for seven weeks by gavage to rats in the first, second, third and fourth groups, respectively. Body organ weights, antioxidant enzyme activities were investigated. The results showed that there was a decrease in malondialdehyde (MDA) level and marked increases in GSH, GPx and CAT activities, were observed in rats treated with different concentrations of Pomegranate juice.

Moreover, Mohan *et al.* (2010) studied the effect of Pomegranate juice extract which was orally given in a dose of 100 mg/kg and 300 mg/kg; orally for four weeks on blood pressure in diabetic Wistar rats. The results showed that there was a reduction in oxidative stress induced by diabetes and Angiotensin II. Pomegranate juice treatment also caused a significant decrease in levels of thiobarbituric acid reactive substances

(TBARS) in kidney tissues and pancreas, while the activity of enzymes SOD, CAT and GSH showed significant elevation.

Abdel Moneim *et al.* (2011) investigated the antioxidant properties of Pomegranate in hepatic and renal tissues of rats. Eighteen adult male albino rats were randomly divided into three groups, six rats of each. The first group served as control and received saline (0.2 ml saline/ rat) by oral administration via stomach (gastric) tube. The second group received oral administration of three ml/kg Pomegranate juice for twenty-one days and served as Pomegranate juice group. The third group received oral administration of 200 mg/kg methanol extract of Pomegranate peel for twenty-one days and served as methanol extract of Pomegranate peel (MEPP) group. The authors concluded that administration of Pomegranate juice and MEPP reduces lipid peroxidation and NO in homogenate of both liver and kidney tissues. A significant increase in SOD and CAT activities of rats received Pomegranate was observed. These findings demonstrated that Pomegranate has a potent antioxidative effect.

## **2.6 Safety of Pomegranate:**

Pomegranate and its constituents have been safely consumed for centuries without adverse effects. Studies of Pomegranate constituents in animals at concentrations and levels commonly used in folk and traditional medicine note no toxic effects (Vidal *et al.*, 2003). Toxicity of the polyphenol antioxidant punicalagin, abundant in Pomegranate juice, was evaluated in rats. The results showed neither toxic effects nor significant differences in the treatment group compared to controls were reported. This

finding was confirmed by the normal histopathological picture of rat organs (Cerdeira *et al.*, 2003).

Aviram *et al.* (2004) studied the effect of Pomegranate juice consumption (50 ml/day which contain 1.5 mmoles of total polyphenols) for up to three years on ten patients with carotid artery stenosis. The results showed that there were no toxic effects on blood chemistry and kidney, liver, and heart functions.

Heber *et al.* (2007) investigated the safety of Pomegranate fruit extract (PFE) tablets in amounts up to 1.420 mg/day (870 mg gallic acid equivalents (GAEs)) for twenty-eight days on eighty-six overweight human volunteers. The results showed that there were no adverse events reported or adverse changes in blood and urine laboratory values were observed.

## **CHAPTER III**

# **MATERIAL AND METHODS**

## **Chapter III**

### **Material and Methods**

In the present study, the biological and histopathological effects of Pomegranate juice at three concentration levels were investigated on hypercholesterolemic rats.

#### **3.1 Material:**

##### **3.1.1 Pomegranate:**

Ripe Pomegranate fruits used in this study were purchased from a local market, Jeddah, Kingdom of Saudi Arabia. The Pomegranate plant was grown in Taif city, a west province of the Kingdom of Saudi Arabia.

##### **3.1.2 Cholesterol:**

Cholesterol was purchased from Sigma-Aldrich Company, St. Louis, Missouri, USA, in the form of white crystalline powder in plastic bottles each containing 100 gram.

### **3.1.3 Rats:**

A total number of thirty five adult male albino rats of Wistar strain of 6-8 weeks old and weighed  $150 \pm 30$  grams were used in this study. The rats were obtained from Faculty of Pharmacy, King Abdul-Aziz University, Jeddah, Saudi Arabia.

### **3.1.4 Kits for Biochemical Analysis:**

Commercial diagnostic kits for estimating serum lipid profile (total cholesterol, triglycerides and lipoprotein fractions) were obtained from Randox Laboratories, U.K. The kits for estimating liver function enzymes (AST and ALT) were obtained from Diamond Company, Hannover, Germany. Antioxidant enzymes commercial kits were purchased from Roche Diagnostic laboratories, Germany.

## **3.2 Methods:**

### **3.2.1 Preparation of the Basal Diet:**

The basal diet for rats was prepared using AIN-93 according to Reeves *et al.* (1993). The basal diet consists of the following: Protein (Casein) 20%; Sucrose 10%; Corn Oil 4%; Choline Chloride 0.2%; Vitamin mixture 1%; Salt mixture 3.5%; Fibers (Cellulose) 5% and the remainder is Corn Starch up to 100%.

### **3.2.2 Induction of Hypercholesterolemia:**

Induction of hypercholesterolemia was done by feeding rats on cholesterol containing diet (experimental diet) which was prepared by formulated basal diet with

2% Cholesterol and 0.5% Cholic acid for 4 weeks according to the method described by Shinnick *et al.* (1990).

### **3.2.3 Preparation of Pomegranate Juice:**

The fruits of fresh Pomegranate were washed and manually peeled, without separating the seeds. Pomegranate juice was obtained using a commercial blender (Moulinex, France), filtrated with a Buchner funnel (Faria *et al.*, 2007).

### **3.2.4 Experimental Design and Grouping of Rats:**

The experiment was performed on thirty five male mature Wistar rats. Animals were distributed randomly into 5 equal groups. Rats were housed in standard plastic cages at a room temperature maintained at  $24 \pm 2$  °C, with fixed 12 hour lighting system.

All rats were allowed to free access to basal diet and water for one week before starting the experiment for acclimatization. After acclimatization period, the rats were allocated in to the following groups:-

**Group (1):** Rats fed on the basal diet only, kept as a negative control group (Con -ve) and received oral gavage of distilled water.

The other four groups were fed on experimental diet for four weeks. After this period, blood samples were taken for measuring total cholesterol level. Rats with blood cholesterol level  $\geq 5.2$  mmol /L were considered to be hypercholesterolemic (Iqbal *et al.*, 2011). These rats were distributed in to the following groups:-

**Group (2):** Rats fed on experimental diet only, kept as a positive control group (Con +ve) and received oral gavage of distilled water.



**Group (3):** Rats fed on experimental diet and orally given Pomegranate juice in a dose of 1 ml/kg body weight (b. wt.).

**Group (4):** Rats fed on experimental diet and orally given Pomegranate juice in a dose of 3 ml/kg b. wt.

**Group (5):** Rats fed on experimental diet and orally given Pomegranate juice in a dose of 5 ml/kg b. wt.

**3.2.5 Determination of Feed Intake, Body Weight Gain percent (BWG %) and Feed Efficiency Ratio (FER):**

Daily feed intake (FI) per group was calculated throughout the experimental period (28 days). The biological values of different diets were assessed by the determination of body weight gain percent (BWG %) which was calculated at the end of the experimental period as well as feed efficiency ratio (FER) was calculated twice a week, according to the method of Chapman *et al.* (1959). Using the following equations:

$$\text{Body weight gain percent (BWG \%)} = \frac{\text{Final body weight} - \text{Initial body weight}}{\text{Initial body weight}} \times 100.$$

Feed efficiency ratio was calculated as follows:

$$\text{Feed efficiency ratio (FER)} = \frac{\text{Gain in body weight (g)}}{\text{Feed consumed (g)}}$$

At the end of the experimental period, all rats were fasted overnight then sacrificed. Blood samples were immediately collected from the retro orbital plexus with

capillary tubes under mild ether anesthesia, into clean dried centrifuge tubes. The tubes were then centrifuged at 3000 rpm for 15 minutes. Clear serum samples were carefully separated using Pasteur pipettes, and frozen at - 20° C until biochemical analysis (Margoni *et al.*, 2011). The liver and heart were removed by careful dissection and blotted free of adhering blood immediately after sacrificing the rats. The organs were washed with cold saline solution and dried between two filter papers then weighed and they saved for the histopathological examination. Calculation of the relative organs weight was done according to the following equation:

$$\text{Organ relative weight} = \frac{\text{Organ weight}}{\text{Animal final bodyweight}} \times 100.$$

Livers and hearts were kept in 10% neutral buffered formalin pending for the histopathological examination.

### **3.2.6 Biochemical Analyses:**

The biochemical analyses were measured using different methods as explained below:

#### **3.2.6.1 Estimation of Total Polyphenol Concentration in Pomegranate Juice:**

Total polyphenol concentrations in Pomegranate juice were determined spectrophotometrically according to the method of Singleton and Rossi (1965) and modified by Narr Ben *et al.* (1996) for small volumes. Gallic acid stock solution was prepared in ethanol at a concentration of 1mM and used as standard solution. The results were recorded as gallic acid equivalents (GAEs).

### **3.2.6.2 Serum Analysis:**

#### **3.2.6.2.1 Determination of Serum Total Cholesterol (TC):**

Serum cholesterol was determined according to the method described by Allain *et al.* (1974), using a Spectrophotometer (Thermo Fisher Scientific Genesys, USA) adjusted at 500 nm wave length. The concentration of the sample was calculated from the following equation:-

$$\text{TC concentration (mmol/L)} = \frac{\text{Absorbance of sample}}{\text{Absorbance of standard}} \times 5.17.$$

#### **3.2.6.2.2 Determination of Serum Triglycerides (TG):**

Concentrations of serum triglycerides were determined according to the method described by Trinder (1969), using a Spectrophotometer (Thermo Fisher Scientific Genesys, USA) at 500 nm wave length. The concentration of the sample was calculated from the following equation:

$$\text{TG concentration (mmol/L)} = \frac{\text{Absorbance of sample}}{\text{Absorbance of standard}} \times 2.25.$$

#### **3.2.6.2.3 Determination of High Density Lipoprotein Cholesterol (HDL-c):**

Serum high density lipoprotein cholesterol was calorimetrically determined according to the method described by Lopes-Virella *et al.* (1977), using a Spectrophotometer (Thermo Fisher Scientific Genesys, USA) at 500 nm wave length. The concentration of the sample was calculated from the following equation:-

$$\text{HDL-c concentration (mmol/L)} = \frac{\text{Absorbance of sample}}{\text{Absorbance of standard}} \times 4.65.$$

#### 3.2.6.2.4 Determination of Low Density Lipoprotein Cholesterol (LDL-c):

Serum low density lipoproteins cholesterol was calorimetrically determined according to the method described by Fridewald *et al.* (1972). The concentration of the sample was calculated from the following equation:-

$$\text{LDL-c concentration (mmol/L)} = \text{Total cholesterol} - \left( \frac{\text{TG}}{2.2} + \text{HDL-c} \right).$$

#### 3.2.6.2.5 Determination of Very Low Density Lipoprotein Cholesterol (VLDL-c):

Serum very low density lipoproteins cholesterol was calorimetrically determined according to the method described by Fridewald *et al.* (1972). The concentration of the sample was calculated from the following equation:

$$\text{VLDL-c concentration (mmol/L)} = \frac{\text{Triglycerides}}{2.2}.$$

#### 3.2.6.2.6 Determination of Liver Enzyme Activity:

##### 3.2.6.2.6.1 Determination of AST and ALT enzyme activity:

Serum aspartate aminotransferase (AST) activity and alanine aminotransferase (ALT) activity were estimated enzymatically based on color reaction formation. The developed color was measured according to the method described by Bergmeyer *et al.* (1978) using a Spectrophotometer (Thermo Fisher Scientific Genesys, USA) adjusted at

505 nm wave length. The concentration was calculated by matching the reading of optical density of concentration of the sample with that of the standard solution.

### **3.2.6.3 Determination of Antioxidant Enzyme Activity:**

The frozen liver samples were thoroughly homogenized on ice with Tri- HCL buffer solution (PH 7.4) to obtain 10% tissue homogenate. The prepared liver homogenates were used for measurement of activities of antioxidant enzymes.

#### **3.2.6.3.1 Determination of Catalase (CAT):**

Catalase activity was measured by monitoring the decomposition of H<sub>2</sub>O<sub>2</sub> at 240 nm wave length (extinction coefficient  $0.00394 \pm 0.0002 \text{ mM}^{-1} \text{ mm}^{-1}$ ) according to the method described by Sinha (1972). CAT enzyme activity was expressed as U of catalase/mg protein (1 unit of catalase is defined as the amount of enzyme required to hydrolyze 1  $\mu\text{mol}$  of H<sub>2</sub>O<sub>2</sub> per min).

#### **3.2.6.3.2 Determination of Superoxide Dismutase (SOD):**

Superoxide dismutase (SOD) activity was assessed using a Xanthine oxidase system to generate superoxide radicals (O<sub>2</sub><sup>-</sup>) as described by Kakkar *et al.* (1984). The rate of suppression of the reduction of Nitro tetrazolium blue (NTB) by O<sub>2</sub><sup>-</sup> was monitored at 550 nm wave length. SOD enzyme activity was expressed as U of SOD/mg of protein (1 unit of SOD is defined as the amount of enzyme required to inhibit the rate of reduction of NTB by 50%).

### **3.2.6.3.3 Determination of Glutathione Peroxidase (GPx):**

Glutathione peroxidase (GPx) activity was assayed by NADPH oxidation at 340 nm wave length when GSSG is reduced back by glutathione reductase as described by Paglia and Valentine (1967), using cumene hydroperoxide (relatively stable organic peroxide, acts as oxidizing agent) as a substrate. Glutathione peroxidase activity was calculated using an extinction coefficient of  $6.22 \text{ mM}^{-1} \text{ cm}^{-1}$  and expressed as U of GPx /mg of protein (1 unit of GPx is defined as the amount of enzyme required to convert 1 nmol NADPH to  $\text{NADP}^+$  per min).

### **3.2.7 Histopathological Examination:**

Specimens from the halves of liver and heart were taken immediately after weighed the organs of the rats and immersed in 10% neutral buffered formalin. The fixed specimens were then trimmed, washed, and dehydrated in ascending grades of alcohol, then cleared in xylene, and stained with Hematoxylin and Eosin (H&E) and examined microscopically according to Bancroft and Gamble (2008).

### **3.3 Statistical Analysis:**

Statistical analyses were carried out using Statistical Package for the Social Sciences (SPSS) for Windows, version 18 (SPSS Inc., Chicago, IL, USA). The obtained data were presented as means  $\pm$  standard deviation (SD). Statistical analysis of variance between mean values of different groups was performed using one way ANOVA test followed by the least significant difference (LSD) test to determine the variance between all treatments. Differences were considered significant at  $P < 0.05$ .

# **CHAPTER IV**

## **RESULTS**

## Chapter IV

### RESULTS

In the current study, the results of estimation of total polyphenols content of Pomegranate juice, effect of Pomegranate juice on initial body weight, final body weight, daily feed intake, body weight gain percent (BWG %), feed efficiency ratio (FER), relative organs weight to body weight as well as some biochemical constituents in serum of hypercholesterolemic rats and histopathological examination of liver and heart are depicted in Tables 4.1 to 4.8 and illustrated in Figures 4.1 to 4.28. These effects were explored when Pomegranate juice was orally given to hypercholesterolemic rats at three dosage levels for 28 days.

#### 4.1 Estimation of total polyphenols content of Pomegranate juice:

The total polyphenols content of Pomegranate juice as gallic acid equivalents was  $3.9 \pm 0.1$  mg /ml as recorded in Table 4.1.

**Table 4.1 Total polyphenols as gallic acid equivalents (GAEs), of Pomegranate juice**

Beverage	Gallic acid equivalents GAEs (mg/ml)
Pomegranate juice	$3.9 \pm 0.1$

Mean  $\pm$  SD of triplicate measurements.



#### **4.2 Effect of oral administration of Pomegranate juice on initial body weight, final body weight and body weight gain percent (BWG %) in hypercholesterolemic rats:**

The initial body weight, final body weight and body weight gain percent (BWG %) of hypercholesterolemic rats treated with Pomegranate juice at three dosage levels (1, 3 and 5 ml/kg b. wt.) are presented in Table 4.2 and Figures 4.1, 4.2 and 4.3.


Data recorded in Table 4.2 and Figure 4.1 showed that there was no significant differences in initial body weight between all experimental groups. A significant ( $P < 0.05$ ) increase was observed in the final body weight of hypercholesterolemic rats (positive control group), compared to the normal rats (negative control group) as shown in Table 4.2 and Figure 4.2. Oral administration of Pomegranate juice in doses of 3 and 5 ml/kg b. wt., significantly ( $P < 0.05$ ) decreased the final body weight when compared to the hypercholesterolemic rats (positive control group) by 7.8 and 9.03 % respectively. No significant difference was observed between the group given the low dose (1 ml/kg b. wt.) of Pomegranate juice and the positive control group.

Concerning body weight gain percent, the results showed that there was a significant increase in the hypercholesterolemic rats (positive control group) when compared to normal rats (negative control group) by 14.87 %. Oral administration of Pomegranate juice in doses of 1, 3 and 5 ml/kg b. wt., significantly ( $P < 0.05$ ) decreased the BWG % by 5.4, 11.15 and 11.4 % respectively, when compared to hypercholesterolemic rats (positive control group) as shown in Table 4.2 and Figure 4.3.

**Table 4.2 Effect of oral administration of Pomegranate juice on initial body weight, final body weight and body weight gain % ( BWG %) in hypercholesterolemic rats**


<b>Parameter</b>	<b>Initial weight</b>	<b>Final weight</b>	<b>Body weight gain</b>
<b>Groups</b>	<b>(g)</b>	<b>(g)</b>	<b>(%)</b>
<b>Negative control</b>	247.54 ± 3.29 <sup>a</sup>	280.40 ± 1.87 <sup>b</sup>	13.29 ± 1.15 <sup>c</sup>
<b>Positive control</b>	245.88 ± 3.40 <sup>a</sup>	315.10 ± 4.45 <sup>a</sup>	28.16 ± 1.30 <sup>a</sup>
<b>Pomegranate juice</b>	250.08 ± 4.24 <sup>a</sup>	307.02 ± 8.78 <sup>a</sup>	22.76 ± 2.18 <sup>b</sup>
<b>1 ml/kg</b>			
<b>Pomegranate juice</b>	248.34 ± 3.89 <sup>a</sup>	290.50 ± 3.28 <sup>b</sup>	17.01 ± 3.05 <sup>c</sup>
<b>3 ml/kg</b>			
<b>Pomegranate juice</b>	245.56 ± 6.60 <sup>a</sup>	286.62 ± 3.43 <sup>b</sup>	16.76 ± 1.99 <sup>c</sup>
<b>5 ml/kg</b>			

Data are presented as means ± standard deviation, (n = 7 for each group).  
 Values with different superscripts within each column are significantly different at P < 0.05.  
 Values with similar or partially similar superscripts are non significant.




Values with different superscripts within the column are significantly different at  $P < 0.05$ .

**Figure 4.1 Effect of oral administration of Pomegranate juice on the initial body weight in hypercholesterolemic rats**



Values with different superscripts within the column are significantly different at  $P < 0.05$ .

**Figure 4.2 Effect of oral administration of Pomegranate juice on the final body weight in hypercholesterolemic rats**



Values with different superscripts within the column are significantly different at  $P < 0.05$ .

**Figure 4.3 Effect of oral administration of Pomegranate juice on the body weight gain percent (BWG %) in hypercholesterolemic rats**

### **4.3 Effect of oral administration of Pomegranate juice on feed intake and feed efficiency ratio (FER) in hypercholesterolemic rats:**

Feed intake and feed efficiency ratio (FER) of hypercholesterolemic rats orally given Pomegranate juice at three dosage levels (1, 3 and 5 ml/kg b. wt.) are shown in Table 4.3 and Figures 4.4 and 4.5.


Feed intake was significantly ( $P < 0.05$ ) increased in the hypercholesterolemic rats (positive control group), compared to normal rats (negative control group) by 1.61 %. Oral administration of Pomegranate juice at three dosage levels 1, 3 and 5 ml/kg b. wt., decreased feed intake as compared to hypercholesterolemic rats (positive control group) by 14.76, 20.66 and 25.10 % respectively.

It is clear from Table 4.3 and Figure 4.5 that FER in hypercholesterolemic rats (positive control group) significantly ( $P < 0.05$ ) increased when compared to normal rats (negative control group) by 93.6 %. Significant ( $P < 0.05$ ) decreases were observed in rats orally given Pomegranate juice in doses of 3 and 5 ml/kg b. wt., as compared to the positive control group by 23.07 and 20.87 % respectively. The dose 1 ml/kg b. wt., didn't cause a significant change when compared to the positive control group.

**Table 4.3 Effect of oral administration of Pomegranate juice on feed intake and feed efficiency ratio (FER) in hypercholesterolemic rats**

<b>Parameter</b>	<b>Mean of daily feed intake</b>	<b>Feed efficiency</b>
<b>Groups</b>	<b>(g/d)</b>	<b>ratio (FER)</b>
<b>Negative control</b>	26.67 <sup>b</sup>	0.047 ± 0.005 <sup>d</sup>
<b>Positive control</b>	27.10 <sup>a</sup>	0.091 ± 0.002 <sup>a</sup>
<b>Pomegranate juice</b>	23.10 <sup>c</sup>	0.088 ± 0.009 <sup>a, b</sup>
<b>1 ml/kg</b>		
<b>Pomegranate juice</b>	21.50 <sup>d</sup>	0.070 ± 0.01 <sup>c</sup>
<b>3 ml/kg</b>		
<b>Pomegranate juice</b>	20.30 <sup>e</sup>	0.072 ± 0.007 <sup>b, c</sup>
<b>5 ml/kg</b>		


Data are presented as means ± standard deviation, (n = 7 for each group).  
 Values with different superscripts within the column are significantly different at P < 0.05.  
 Values with similar or partially similar superscripts are non significant.



Values with different superscripts within the column are significantly different at  $P < 0.05$ .

**Figure 4.4 Effect of oral administration of Pomegranate juice on feed intake in hypercholesterolemic rats**





Values with different superscripts within the column are significantly different at  $P < 0.05$ .

**Figure 4.5 Effect of oral administration of Pomegranate juice on feed efficiency ratio (FER) in hypercholesterolemic rats**

#### **4.4 Effect of oral administration of Pomegranate juice on liver and heart relative weight to the body weight in hypercholesterolemic rats:**


Concerning the relative organs weight to the body weight of rats, the results showed that hypercholesterolemic rats had a significant ( $P < 0.05$ ) increase in the relative weights of liver and heart as compared to normal rats (negative control group) by 0.97 and 0.11 % respectively as depicted in Table 4.4 and Figures 4.6 and 4.7.

Oral administration of Pomegranate juice in a dose of 3 ml/ kg b. wt., significantly decreased liver and heart weight compared to hypercholesterolemic rats (positive control group) by 0.85 and 0.09 % respectively. No significant changes were observed in rats orally given Pomegranate juice in doses of 1 and 5 ml/ kg b. wt., for both organs when compared to hypercholesterolemic rats (positive control group).

**Table 4.4 Effect of oral administration of Pomegranate juice on liver and heart relative weight in hypercholesterolemic rats**


<b>Parameter</b>	<b>Relative</b>	<b>Relative</b>
<b>Groups</b>	<b>liver weight</b>	<b>heart weight</b>
<b>Negative control</b>	2.75 ± 0.24 <sup>b</sup>	0.28 ± 0.04 <sup>b</sup>
<b>Positive control</b>	3.72 ± 0.58 <sup>a</sup>	0.39 ± 0.05 <sup>a</sup>
<b>Pomegranate juice</b>	2.99 ± 0.20 <sup>a, b</sup>	0.35 ± 0.05 <sup>a, b</sup>
<b>1 ml/kg</b>		
<b>Pomegranate juice</b>	2.87 ± 0.37 <sup>b</sup>	0.30 ± 0.03 <sup>b</sup>
<b>3 ml/kg</b>		
<b>Pomegranate juice</b>	2.97 ± 0.33 <sup>a, b</sup>	0.34 ± 0.04 <sup>a, b</sup>
<b>5 ml/kg</b>		

Data are presented as means ± standard deviation, (n = 7 for each group).  
 Values with different superscripts within the column are significantly different at P < 0.05.  
 Values with similar or partially similar superscripts are non significant.



Values with different superscripts within the column are significantly different at  $P < 0.05$ .

**Figure 4.6 Effect of Pomegranate juice on relative weight of liver of hypercholesterolemic rats**



Values with different superscripts within the column are significantly different at  $P < 0.05$ .

**Figure 4.7 Effect of Pomegranate juice on relative weight of heart of hypercholesterolemic rats**

#### **4.5 Effect of oral administration of Pomegranate juice on the serum level of total cholesterol (TC) and triglycerides (TG) in hypercholesterolemic rats:**

Results of biochemical analyses revealed that hypercholesterolemic rats (positive control group) had a significant ( $P<0.05$ ) increase in total cholesterol (TC) by 177.4 % and triglycerides (TG) by 77.77 % compared to normal rats (negative control group) as recorded in Table 4.5 and shown in Figures 4.8 and 4.9.


Oral administration of Pomegranate juice at the tested doses 1, 3 and 5 ml/kg b. wt., significantly ( $P<0.05$ ) decreased serum TC by 33.92, 59.01 and 55.83 % respectively compared to hypercholesterolemic rats (positive control group) as shown in Table 4.5 and Figure 4.8.

Oral administration of 1 and 5 ml/kg b. wt., of Pomegranate juice to hypercholesterolemic rats significantly ( $P<0.05$ ) reduced serum TG levels by 40 and 40.62 % respectively when compared to hypercholesterolemic rats (positive control group). The dose of 3 ml/kg b. wt., caused no significant change when compared to the positive control group as shown in Table 4.5 and Figure 4.9.

**Table 4.5 Effect of oral administration of Pomegranate juice on the serum levels of total cholesterol (TC) and triglycerides (TG) in hypercholesterolemic rats**

<b>Parameter</b>	<b>TC</b>	<b>TG</b>
<b>Groups</b>	<b>(mmol/L)</b>	<b>(mmol/L)</b>
<b>Negative control</b>	2.04 ± 0.24 <sup>c</sup>	0.90 ± 0.25 <sup>b</sup>
<b>Positive control</b>	5.66 ± 0.79 <sup>a</sup>	1.60 ± 0.19 <sup>a</sup>
<b>Pomegranate juice</b>	3.74 ± 0.62 <sup>b</sup>	0.96 ± 0.29 <sup>b</sup>
<b>1 ml/kg</b>		
<b>Pomegranate juice</b>	2.32 ± 0.19 <sup>c</sup>	1.12 ± 0.33 <sup>a, b</sup>
<b>3 ml/kg</b>		
<b>Pomegranate juice</b>	2.50 ± 0.07 <sup>c</sup>	0.95 ± 0.31 <sup>b</sup>
<b>5 ml/kg</b>		


Data are presented as means ± standard deviation, (n = 7 for each group).  
 Values with different superscripts within the column are significantly different at P < 0.05.  
 Values with similar or partially similar superscripts are non significant.



Values with different superscripts within the column are significantly different at  $P < 0.05$ .

**Figure 4.8 Effect of oral administration of Pomegranate juice on serum total cholesterol (TC) in hypercholesterolemic rats**





Values with different superscripts within the column are significantly different at  $P < 0.05$ .

**Figure 4.9 Effect of oral administration of Pomegranate juice on serum triglycerides (TG) in hypercholesterolemic rats**

#### **4.6 Effect of oral administration of Pomegranate juice on the serum levels of lipoprotein fractions in hypercholesterolemic rats:**

Results in Table 4.6 and Figures 4.10, 4.11 and 4.12 illustrate the effect of different doses of Pomegranate juice on serum levels of lipoprotein fractions in hypercholesterolemic rats.

Results of high density lipoprotein cholesterol (HDL-c) are recorded in Table 4.6 and shown in Figure 4.10. The obtained data indicated that hypercholesterolemic rats (positive control group) had a significant ( $P < 0.05$ ) decrease in serum of hypercholesterolemic rats when compared with the normal rats (negative control group) by 22 %. Oral administration of 1, 3 and 5 ml/kg b. wt., of Pomegranate juice to hypercholesterolemic rats significantly ( $P < 0.05$ ) increases serum HDL-c level by 54.69, 50 and 71.88 % respectively when compared to hypercholesterolemic rats (positive control group), as shown in Table 4.6 and Figure 4.10.


It is clear from Table 4.6 and Figure 4.11 that hypercholesterolemic rats (positive control group) had a significant ( $P < 0.05$ ) increase in serum level of low density lipoprotein cholesterol (LDL-c) when compared to the normal rats (negative control group) by 382.9 %. Oral administration of Pomegranate juice at three dosage levels significantly ( $P < 0.05$ ) decreased serum levels of LDL-c when compared to hypercholesterolemic rats (positive control group). The decreases in serum levels of LDL-c in rats given Pomegranate juice at doses 1, 3 and 5 ml/kg b. wt., groups were 41.4, 75.75 and 75.25 % respectively.

Concerning serum levels of very low density lipoprotein cholesterol (VLDL-c), the results revealed that hypercholesterolemic rats (positive control group) had a significant ( $P < 0.05$ ) increase in serum level of VLDL-c when compared to normal rats (negative control group) by 75.6 %. Oral administration of Pomegranate juice at 1, 3 and 5 ml/kg b. wt., for 28 days produced significant ( $P < 0.05$ ) decreases in serum levels of VLDL-c by 40.27, 43.05 and 40.27% respectively, when compared to the hypercholesterolemic rats(positive control group) as shown in Table 4.6 and Figure 4.12.

**Table 4.6 Effect of oral administration of Pomegranate juice on the serum levels of lipoprotein fractions in hypercholesterolemic rats**


<b>Parameter</b>	<b>HDL-c</b>	<b>LDL-c</b>	<b>VLDL-c</b>
<b>Groups</b>	<b>(mmol/L)</b>	<b>(mmol/L)</b>	<b>(mmol/L)</b>
<b>Negative control</b>	0.82 ± 0.09 <sup>a, b</sup>	0.82 ± 0.24 <sup>c</sup>	0.41 ± 0.11 <sup>b</sup>
<b>Positive control</b>	0.64 ± 0.09 <sup>c</sup>	3.96 ± 0.35 <sup>a</sup>	0.72 ± 0.19 <sup>a</sup>
<b>Pomegranate juice</b> <b>1 ml/kg</b>	0.99 ± 0.23 <sup>a, b</sup>	2.32 ± 0.68 <sup>b</sup>	0.43 ± 0.13 <sup>b</sup>
<b>Pomegranate juice</b> <b>3 ml/kg</b>	0.96 ± 0.19 <sup>a, b</sup>	0.96 ± 0.29 <sup>c</sup>	0.41 ± 0.16 <sup>b</sup>
<b>Pomegranate juice</b> <b>5 ml/kg</b>	1.10 ± 0.28 <sup>a</sup>	0.98 ± 0.24 <sup>c</sup>	0.43 ± 0.15 <sup>b</sup>

Data are presented as means ± standard deviation, (n = 7 for each group).  
 Values with different superscripts within the column are significantly different at P < 0.05.  
 Values with similar or partially similar superscripts are non significant.




Values with different superscripts within the column are significantly different at  $P < 0.05$ .

**Figure 4.10 Effect of oral administration of Pomegranate juice on serum levels of high density lipoprotein cholesterol (HDL-c) in hypercholesterolemic rats**



Values with different superscripts within the column are significantly different at  $P < 0.05$ .

**Figure 4.11 Effect of oral administration of Pomegranate juice on serum levels of low density lipoprotein cholesterol (LDL-c) in hypercholesterolemic rats**



Values with different superscripts within the column are significantly different at  $P < 0.05$ .

**Figure 4.12 Effect of oral administration of Pomegranate juice on serum levels of very low density lipoprotein cholesterol (VLDL-c) in hypercholesterolemic rats**

#### **4.7 Effect of oral administration of Pomegranate juice on serum levels of liver function enzymes in hypercholesterolemic rats**

Results of liver function tests of hypercholesterolemic rats orally given Pomegranate juice at three dosages levels 1, 3 and 5 ml/kg b. wt., are shown in Table 4.7 and Figures 4.13 and 4.14.

It is clear from Table 4.7 and Figures 4.13 and 4.14 that hypercholesterolemic rats (positive control group) had significant ( $P < 0.05$ ) increases in serum levels of AST and ALT enzymes in serum of hypercholesterolemic rats when compared to the normal rats (negative control group) by 92.57 and 86.9 % respectively.


Oral administration of 1, 3 and 5 ml/kg b. wt., of Pomegranate juice to hypercholesterolemic rats significantly ( $P < 0.05$ ) reduced serum AST enzyme level by 12.84, 12.77 and 15.38 % respectively as compared to hypercholesterolemic rats (positive control group), as shown in Table 4.7 and Figure 4.13. The corresponding percentages of decreased ALT were 13.40, 16.40 and 23% respectively as compared to the hypercholesterolemic rats (positive control group) as shown in Table 4.7 and Figure 4.14.



**Table 4.7 Effect of oral administration of Pomegranate juice on serum levels of liver function enzymes in hypercholesterolemic rats**


<b>Parameter</b>	<b>AST (U/L)</b>	<b>ALT (U/L)</b>
<b>Groups</b>		
<b>Negative control</b>	55.24 ± 2.33 <sup>c</sup>	26.74 ± 0.88 <sup>d</sup>
<b>Positive control</b>	106.38 ± 4.33 <sup>a</sup>	50.00 ± 1.01 <sup>a</sup>
<b>Pomegranate juice</b>	92.72 ± 1.59 <sup>b</sup>	43.30 ± 0.47 <sup>b</sup>
<b>1 ml/kg</b>		
<b>Pomegranate juice</b>	92.80 ± 1.72 <sup>b</sup>	41.80 ± 0.62 <sup>b</sup>
<b>3 ml/kg</b>		
<b>Pomegranate juice</b>	90.02 ± 0.22 <sup>b</sup>	38.50 ± 1.10 <sup>c</sup>
<b>5 ml/kg</b>		

Data are presented as means ± standard deviation, (n = 7 for each group).  
 Values with different superscripts within the column are significantly different at P < 0.05.  
 Values with similar or partially similar superscripts are non significant.



Values with different superscripts within the column are significantly different at  $P < 0.05$ .

**Figure 4.13 Effect of oral administration of Pomegranate juice on serum levels of Aspartate aminotransferases (AST) in hypercholesterolemic rats**



Values with different superscripts within the column are significantly different at  $P < 0.05$ .

**Figure 4.14 Effect of oral administration of Pomegranate juice on serum levels of Alanine aminotransferases (ALT) in hypercholesterolemic rats**

**4.8 Effect of oral administration of Pomegranate juice on liver homogenates levels of catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GPx) in hypercholesterolemic rats:**


From data recorded in Table 4.8 and Figures 4.15, 4.16 and 4.17 it could be noticed that hypercholesterolemic rats (control positive group) had significant ( $P < 0.05$ ) decreases in liver homogenates levels of catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GPx) enzymes when compared to normal rats (negative control group) by 35.33, 32.81 and 23.65 % respectively. Oral administration of Pomegranate juice at the small dose 1 ml/kg b. wt., showed non significant changes in liver homogenates levels of CAT, SOD and GPx serum when compared to hypercholesterolemic rats (positive control group).

Administration of Pomegranate juice at doses 3 and 5 ml/kg b. wt., showed significant ( $P < 0.05$ ) increase in CAT enzyme liver homogenates level by 44.32 and 49.48 % respectively when compared to hypercholesterolemic rats (positive control group). The corresponding percentages of increased of SOD were 41.86 and 58.14 % respectively when compared to hypercholesterolemic rats (positive control group). Regarding GPx enzyme level, a significant ( $P < 0.05$ ) increase was recorded in rats orally given Pomegranate juice in doses of 3 and 5 ml/kg b. wt., by 30.15 and 30.32 % respectively as compared to hypercholesterolemic rats (positive control group).

**Table 4.8 Effect of oral administration of Pomegranate juice on liver homogenates levels of catalase (CAT), glutathione peroxidase (GPx) and superoxide dismutase (SOD) enzymes in hypercholesterolemic rats**


<b>Parameter</b>	<b>CAT</b>	<b>SOD</b>	<b>GPx</b>
<b>Groups</b>	<b>(U/mg tissue)</b>	<b>(U/mg tissue)</b>	<b>(U/mg tissue)</b>
<b>Control negative</b>	1.50 ± 0.45 <sup>a</sup>	1.28 ± 0.21 <sup>a</sup>	62.90 ± 1.41 <sup>a</sup>
<b>Control positive</b>	0.97 ± 0.05 <sup>b</sup>	0.86 ± 0.09 <sup>b</sup>	48.02 ± 1.19 <sup>b</sup>
<b>Pomegranate juice</b>	1.09 ± 0.11 <sup>a, b</sup>	1.06 ± 0.11 <sup>a, b</sup>	49.42 ± 0.73 <sup>b</sup>
<b>1 ml/kg</b>			
<b>Pomegranate juice</b>	1.40 ± 0.07 <sup>a</sup>	1.22 ± 0.05 <sup>a</sup>	62.50 ± 0.67 <sup>a</sup>
<b>3 ml/kg</b>			
<b>Pomegranate juice</b>	1.45 ± 0.01 <sup>a</sup>	1.36 ± 0.21 <sup>a</sup>	62.58 ± 0.97 <sup>a</sup>
<b>5 ml/kg</b>			

Data are presented as means ± standard deviation, (n = 7 for each group).  
 Values with different superscripts within the column are significantly different at P < 0.05.  
 Values with similar or partially similar superscripts are non significant.




Values with different superscripts within the column are significantly different at  $P < 0.05$ .

**Figure 4.15 Effect of oral administration of Pomegranate juice on liver homogenates levels of catalase (CAT) in hypercholesterolemic rats**



Values with different superscripts within the column are significantly different at  $P < 0.05$ .

**Figure 4.16 Effect of oral administration of Pomegranate juice on liver homogenates levels of superoxide dismutase (SOD) in hypercholesterolemic rats**



Values with different superscripts within the column are significantly different at  $P < 0.05$ .

**Figure 4.17 Effect of oral administration of Pomegranate juice on liver homogenates levels of glutathione peroxidase (GPx) in hypercholesterolemic rats**



## **4.9 Histopathological Examination:**


### **4.9.1 Liver:**

Histological examination of liver of the negative control group demonstrated normal histological pattern where hepatic lobules appeared as hexagonal masses of liver cells (hepatocytes) radiating from a central vein. Blood sinusoids appeared between cords of hepatocytes. The hepatocytes had a hexagonal outline with central rounded nucleus. The cytoplasm showed some vacuoles Figure 4.18.


Compared to negative control Figure 4.18, examination of liver sections of the positive control (hypercholesterolemic rats) group revealed marked impairment of the normal structural organization of hepatic lobules in many areas and deposition of large lipid droplet in cells. Hepatocytes showed vacuolar degeneration, swollen and vacuolated cells, and some nuclei revealed clear signs of dark small pyknosis as illustrated in Figures 4.19 and 4.20.

Examination of liver of hypercholesterolemic rat treated by Pomegranate juice in a dose of 1 ml/kg b. wt., revealed a marked improvement with normal hepatocytes, congested central vein when compared to the positive control group Figure 4. 21. The hypercholesterolemic rat orally given Pomegranate juice in a dose of 3 mg/kg b. wt., showed marked improvement from changes caused by cholesterol except of few residual cells with fine lipid droplets, or scattered dark apoptotic cells and some sections showed bile duct proliferation Figure 4.22.


Sections from liver of hypercholesterolemic rat after treated by Pomegranate juice in a dose of 5 ml/kg b. wt., showed more improvement in histological structure comparing with section of rats that orally given Pomegranate juice in doses of 1 and 3 ml/kg b. wt., The examination section showed almost normal structure with regular arrangement of hepatocyte cell cords and exhibited a reduction in fat accumulation. The hepatocytes around the central vein (CV) showed rounded nuclei and vesicular indicating active cells. Blood sinusoids between the cells had also normal appearance Figure 4.23.




**Figure 4.18 (a-b) Section in the liver of a normal rat (negative control) showing liver cells surrounded by central vein (CV) and peripheral portal structures (dotted black arrows), normal hepatocytes with large central vesicular (black arrows), some cells are binucleated (white arrows) (H & E x 400).**




**Figure 4.19** Section in the liver of hypercholesterolemic rat (positive control) showing foci of lipid droplets deposition within hepatocytes (dotted circles) and the neighboring cells showed vacuolar degeneration (stars) (H & E x 100).




**Figure 4.20 (a-b) Section in the liver of hypercholesterolemic rat (positive control) showing deposition of large lipid droplet in some cells (white arrows). In other cells marked vacuolations were observed (stars), some cells showed dark small degenerated nuclei (black arrows) (H & E x 400).**



**Figure 4.21** Section in the liver of hypercholesterolemic rats after treatment with 1 ml/ kg b. wt., Pomegranate juice showing mild improvement with congested central vein (CV), normal hepatocytes (black arrows) and numerous binucleated cells (white arrows) (H & E x 400).



**Figure 4.22 (a-b) Section in the liver of hypercholesterolemic rat after treatment with 3 ml/kg b. wt., Pomegranate juice showing moderate improvement from degenerative changes except presence of few residual cells with lipid droplets ( thin black arrows) or scattered dark apoptotic cells(dotted arrows) and some showed bile duct proliferation (white arrows) (H & E x 400).**



**Figure 4.23** Section in the liver of hypercholesterolemic rat after treatment with 5 ml/ kg b. wt., Pomegranate juice showing almost normal structure with regular arrangement of hepatic cell cords (black thin arrows) around the central vein (CV), hepatocytes showed rounded and vesicular nuclei indicating active cells. Hepatic sinusoids between the cells showed normal appearance (white arrows) (H & E x 400).




#### **4.9.2 Heart:**

The histological examination of the heart tissue of normal healthy rats showed normal histological architecture manifested by normal cardiac vessels wall thickness, normal size and appearance of cardiac muscles and blood capillaries as illustrated in Figure 4.24. In rats fed on high - cholesterol diet, the examination of the heart revealed some degenerative changes with inflammatory cell infiltration and marked congestion of blood capillaries as demonstrated in Figure 4.25.


The heart sections of the hypercholesterolemic rat orally given Pomegranate juice in a dose of 1ml/kg b. wt., showed a slight improvement of pathological lesions with presence of thickened walls and cholesterol deposition in cardiac vessels. Degenerated dark muscles and congested vessels Figure 4.26. Treatment with Pomegranate juice in a dose of 3 ml/kg b. wt., showed a moderate improvement except cardiac vessels still had focal thickening and some cardiac muscles looked dark Figure 4.27.

Oral administration of Pomegranate juice in a dose of 5 ml/kg b. wt., revealed a marked improvement in histological architecture of the heart tissue except presence of few apoptotic dark cells in the cardiac muscle as shown in Figure 4.28.


From the above mentioned histological findings in liver and heart it seems that the effects of Pomegranate juice on histological pictures of liver and heart were in a dose – dependent manner.





**Figure 4.24 (a-b) Section of heart of normal rats (negative control) showing cardiac vessels with normal wall thickness (black arrows). Cardiac muscles (stars) with normal size and appearance (no degeneration), Blood capillaries were also normal (white arrows) (H &E x 400).**




**Figure 4.25 (a-b) Section from rat heart of hypercholesterolemic rat (positive control) showing degenerative changes of some cardiac muscles (stars) with inflammatory cells infiltration (black arrows). Marked congestion of blood capillaries (dotted arrows) was seen (H & E x 400).**



**Figure 4.26 (a-b) Section from rat heart of hypercholesterolemic rat after treated with 1ml/kg b. wt., Pomegranate juice showing a slight improvement except presence of thickened walls and cholesterol deposition in cardiac vessels (black arrows). Degenerated cardiac muscle (dotted arrows) and congested vessels (white arrows) were also seen (H & E x 400).**



**Figure 4.27 (a-b) Section in cardiac muscles of hypercholesterolemic rat after treatment with 3 ml/kg b. wt., Pomegranate juices showing a moderate improvement (white star). Cardiac blood vessels still showed focal thickening (black arrows). Cardiac muscle showed degeneration (dotted arrows) (H&E x 400).**



**Figure 4.28 (a-b) Section in cardiac wall of hypercholesterolemic rat after treated with 5ml/kg b. wt., Pomegranate juice showing almost normal appearance of cardiac muscles (stars) except few apoptotic dark cells (dotted arrows). Cardiac blood vessels showed normal thickness (thin black arrow). Blood capillaries were normal and not congested (white arrow) (H & E x400).**

# **CHAPTER V**

## **DISCUSSION**

## Chapter V

### Discussion

The present study was performed to elucidate the effect of oral administration of Pomegranate juice at three dosage levels to hypercholesterolemic rats during the experimental period (28 days) on feed intake, body weight gain percent (BWG %), feed efficiency ratio (FER), relative weights of some internal organs and serum levels of total cholesterol (TC), triglycerides (TG), lipoprotein fractions, liver enzymes (AST and ALT) and antioxidant enzymes (CAT, SOD and GPx) as well as the histopathological examination of liver and heart were also carried out.

Concerning feed intake and BWG %, there was a controversy about the effect of high cholesterol supplemented diet on feed intake and BWG % of rats. Ramachandran *et al.* (2003) and Harnafi *et al.* (2009) reported that there were no significant changes of weight gain or there was a linear increase in the weight gain between healthy and hypercholesterolemic rats. Results of the present study revealed incidence of significant increases in feed intake and BWG % of hypercholesterolemic rats when compared to the negative control rats. These findings were in agreement with those obtained by Matos *et al.* (2005); Hossin (2009); Otunola *et al.* (2010); Amin *et al.* (2011) and Nwozo *et al.*



(2011) who confirmed our results. The increase in body weight of hypercholesterolemic rats might be due to the increase of feed and caloric intake by rats. On contrary, the observed body weight loss could be attributed to the reduction in nutrient intake caused by high cholesterol content of the diet which might impair intestinal absorption of protein and other nutrients as suggested by Matos *et al.* (2005).

With regard to the effects of Pomegranate juice when orally given to hypercholesterolemic rats at three dosage levels for 28 days on feed intake and body weight gain, the results revealed that Pomegranate juice significantly reduced feed intake and BWG % when compared to the positive control group. These findings might be due to decreased appetite (anorexia) of rats and/or reduction of intestinal fat absorption or due to an inhibition of pancreatic lipase activity. It is well known that dietary fat is not directly absorbed from the intestine unless it has been subjected to the action of pancreatic lipase (Lei *et al.*, 2007).

In relation to relative weights of liver and heart, there were significant increases in relative weights in liver and heart of hypercholesterolemic rats as compared to the normal group. These results might be due to the accumulation of fat in the liver and heart cells leading to an increase in their weight. These results were confirmed by histopathological examination of these internal organs which showed presence of fatty changes of hepatocytes and focal sarcoplasmic granularity in cardiac myocytes. Our findings were in accordance with those obtained by Matos *et al.* (2005) who reported that the increase in liver weight of hypercholesterolemic rats could be a consequence of the higher fat content (fat/liver). Moreover, Puskas *et al.* (2004) reported that in response

to high cholesterol diet there was an intracellular lipid accumulation in cardiomyocytes of rats, thus leading to an increase in its weight.

Concerning relative weights of liver and heart of Pomegranate juice-treated hypercholesterolemic rats; the results showed that weight of these organs decreased when compared to the hypercholesterolemic group. Our results were in agreement with those of Chidambara *et al.* (2002) who reported that Pomegranate peel when given to rats exhibited protective effects on liver and heart weights.

Results of the present study revealed that feeding of rats on high - cholesterol diet resulted in significant increases in serum levels of TC, TG, LDL-c and VLDL-c accompanied with a significant decrease in HDL-c level as compared to the negative control group. The increases in serum concentrations of the above mentioned parameters and the reduction in serum HDL-c as a result of feeding high - cholesterol diet have been pointed out as risk factors for the development of atherosclerosis and related cardiovascular diseases, which was represented by the decrease in HDL/TC ratio. These results were confirmed by histopathological examination of heart which showed degenerative changes of some cardiac muscles with inflammatory cell infiltration associated with a marked congestion of blood capillaries, compared to the negative control group. The present findings were in the same line as with those reported by Wang and Chen (2004); Gorinstein *et al.* (2006); Frantz *et al.* (2012) who demonstrated that lipid metabolism in rats fed high fat - diet (HFD) presented disorders and levels of serum TC and TG increased significantly, compared with the negative control group.

These results could be explained on the basis that feeding of rats on atherogenic diet leads to increase in cholesterol absorption and hence serum cholesterol increment.

Concerning serum TG level, the present findings agreed with the study of Yugarani *et al.* (1992) who demonstrated that plasma TG level increased significantly after feeding rats on HFD indicating that the increasing in triglycerides is of dietary origin.

Regarding to serum LDL-c and HDL-c levels in rats fed with high cholesterol diet, the current results were in agreement with those of Boden and Pearson (2000); Glass and Witztum (2001); Witztum and Steinberg (2001) and Kumar *et al.* (2010). The previous authors concluded that oxidation of LDL-c resulted in formation of a wide range of biologically active products, including peroxides and malondialdehyde. Moreover, Sezer *et al.* (2011) demonstrated that the oxidative modified lipids and their degradation products are believed to have adverse effects such as pro-inflammatory, immunogenic and cytotoxic activities which contribute to both the initiation and progression of atherosclerotic lesions. Furthermore, Tebib *et al.* (1994) found that activity of the lipoprotein lipase enzyme augmented in hypercholesterolemic rats. Lipase transforms VLDL-c into LDL-c that would lead to an increase in serum concentration of LDL-c. However, Shanmugasundaram *et al.* (1986) reported that the increment of plasma LDL-c level after HFD consumption could be explained via involvement of two enzymes namely cholesterol ester hydrolase (CEH) and cholesterol ester synthetase (CES). These enzymes balance the cholesterol levels in the blood. Hence, it is logical to assume that the elevation in plasma cholesterol is mediated through increased

cholesterol turnover and influenced by the relative balance between CEH and CES activity. With increased estrifying activity (when CEH: CES is lowered) cholesterol will be predominantly in its ester form (as in LDL-c) and can lead to the development and progression of atherosclerosis.

The results concerning serum HDL-c level in hypercholesterolemic group, the present result is well documented by the study of Yugarani *et al.* (1992). It has been reported that cholesterol transport to extra-hepatic tissues is primarily ensured by LDL-c (bad cholesterol); while HDL-c (good cholesterol) has an important role in reversing the cholesterol transport process (Gurr *et al.*, 1989). Hypercholesterolemia is an important etiological factor in coronary heart disease (CHD). Studies have shown that the risk of developing CHD is linearly related to serum cholesterol concentration and LDL-c. On the other side, HDL-c exerts a protective effect (Mattson and Grundy, 1985).

Phenols and flavonoids are very important plant constituents because of their antioxidant activity (Annegowda *et al.*, 2010 and Abdel Moneim, 2012). The antioxidant activity of phenolic compounds is mainly due to their redox properties which play an important role as free radical scavengers, reducing agents, quenchers of singlet oxygen and complexes of pro-oxidant metals (Mustafa *et al.*, 2010). The plant phenolics are commonly present in fruits, vegetables, leaves, nuts, seeds, barks, roots and in other plant parts (Kaviarasan *et al.*, 2007). Pomegranate is an important source of phenols and flavonoids such as anthocyanins, hydrolysable tannins punicalagin and punicalin (Afaq *et al.*, 2005), ellagic and gallic acids (Lansky and Newman, 2007). Pomegranate also contains vitamin C (Turk *et al.*, 2008). The antioxidant and free radicals scavenging

activities of phenolic compounds derived from Pomegranates (Rosenblat *et al.*, 2006) and vitamin C (Sonmez *et al.*, 2005) have been reported.

Furthermore, Rice-Evans *et al.* (1996); Schwenke and Behr (1998); Gil *et al.* (2000); Aviram *et al.* (2002) and Noda *et al.* (2002) concluded that Pomegranate juice is rich in polyphenols and demonstrate high capability in scavenging free radicals and inhibiting LDL-c oxidation *in vitro* and *in vivo*. The present study showed that oral administration of Pomegranate juice at three dosage levels significantly decreased serum level of TC, TG, LDL-c and VLDL-c, but increased HDL-c as compared to the positive control group. These findings correlated with those obtained by Aviram *et al.* (2000) who reported that Pomegranate juice consumption by atherosclerotic mice significantly reduced cholesterol accumulation and foam cell formation in heart tissues. Pomegranate juice treatment significantly and substantially inhibited the progression of atherosclerotic lesions by inhibition of atherogenic modifications of LDL-c, including its retention, oxidation, and aggregation.

Moreover, Tezcan *et al.* (2009) demonstrated that Pomegranate juice increased the level of serum HDL associated paraoxonase 1 (PON1) and decreased the LDL-c susceptibility to aggregation and oxidation. Esmailzadeh *et al.* (2006) reported that diabetic patients with elevated blood lipids who were supplemented with Pomegranate juice for eight weeks experienced significant reductions in their TC and LDL-c. The results of Rosenblat and Aviram (2006) demonstrated that Pomegranate juice can inhibit LDL-c oxidation in 3 ways:

1. Pomegranate juice polyphenols inhibit copper ion-induced LDL-c oxidation, and thus reduce the oxidized LDL (ox-LDL) content.
2. Pomegranate juice polyphenols also increase the activity of serum HDL-c associated paraoxonase 1 (PON1).
3. Paraoxonase 1 (PON1) can in turn hydrolyze lipid peroxides in ox-LDL and convert them to a less atherogenic LDL-c thus causing further reduction in ox-LDL content.

Histopathological examination of heart of hypercholesterolemic rats treated with Pomegranate juice showed improvement in histological structure. Cardiac vessels showed normal thickness. Blood capillaries are normal and not congested as compared to the hypercholesterolemic group. The present results agreed with the study of Rosenblat and Aviram (2006) who reported that the antioxidant and free radicals scavenging property of Pomegranate juice seem to protect the myocardium against oxidative damage in heart tissue.

There has been conflicting reports on the effect of high cholesterol diet on serum biochemical parameters related to hepatic function (AST and ALT). Some reports on the effects of hypercholesterolemia on serum levels of AST and ALT enzymes. In this concern, studies of Lu *et al.* (2007); Prasad (2010) and Saki *et al.* (2011) showed that a high cholesterol diet moderately elevated serum levels of ALT, AST and ALP in rats. On contrary, Molgaard *et al.* (1989) reported that there were no changes in the serum levels of AST and ALT. The discrepancy in the serum levels of these enzymes could be attributed to the levels and duration of hypercholesterolemia (Lu *et al.*, 2007). Our

results revealed that feeding rats on cholesterol-enriched diet produced liver injury as indicated by marked elevation in serum levels of AST and ALT enzymes associated with markedly histopathological changes. These changes consisted of diffuse vacuolar degeneration; fat vacuoles and necrosis of hepatocytes and markedly focal fibrosis as well as a marked decrease in the antioxidant defense system. This decrease was manifested by the significant increase in lipid peroxidation and significant decreases in the activity of antioxidant enzymes namely superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx). These results were in agreement with the previous studies of Miura *et al.* (2000); Arhan *et al.* (2009) and Saki *et al.*(2011) who reported that high cholesterol diet significantly increased serum hepatic enzyme levels (AST and ALT). This increase was attributed to increase the production of free radicals, which initiate lipid peroxidation leading to cellular damage as a result of induction of cytochrome P-450 in the liver producing highly reactive trichloromethyl free radical. This in turn, in the presence of oxygen generated by metabolic leakage from mitochondria causes lipid peroxidation of membrane lipid leading to loss of integrity of cell membranes and damage of hepatic tissue with subsequent increase in serum of these enzymes (AST and ALT).

Results of the present study showed that there were significant decreases in serum levels of AST and ALT enzymes in hypercholesterolemic rats orally given Pomegranate juice in a dose of 1, 3 and 5 ml/kg b. wt., compared to the positive control group. The present results partially agreed with the results obtained by Osman *et al.* (2012) who examined the antioxidant effect of Pomegranate peel and juice on diabetes mellitus induced by alloxan in Female Rats. The results showed that AST and ALT

were significantly increased in diabetic group, but after treatment with peel and juice, AST and ALT levels decreased and become near to the control level especially ALT value. This effect is due to antioxidant content of Pomegranate peel and juice.

Kaur *et al.* (2006) reported that Pretreatment with Pomegranate flower extract, at a dose regimen of 50-150 mg / kg b. wt., for a week, have a protective effect against ferric nitrilotriacetate (Fe-NTA)-induced oxidative stress, as well as hepatic injury. The results showed that there was an inhibition in serum of AST and ALT enzymes which may be due to potent antioxidant and hepatoprotective properties of Pomegranate juice.

The biochemical results of our study were confirmed by histopathological findings, which seen in liver sections. The histological findings of liver of the treated rats showed almost completely normal structure with regular arrangement of hepatocyte cell cords and exhibited reduction in fat accumulation. The nuclei of hepatocytes around the central vein (CV) were rounded and vesicular indicating active cells. Blood sinusoids between the cells had also normal appearance when compared to the positive control group. These histological findings agreed with the study of Fyiad *et al.* (2012) who investigated the effect of Pomegranate juice on nucleic acids alterations and oxidative stress in experimentally hepatitis rats. Results of the previous study revealed that pretreatment with Pomegranate juice (20 ml kg<sup>-1</sup> b. wt., day<sup>-1</sup> for 14 days) effectively hindered the adverse effect of D-Galactosamine / lipopolysaccharide and protected against hepatic damage via suppression of oxidative stress. Histopathological studies of the liver of different groups also supported the protective effects exhibited by Pomegranate juice through restoring the normal hepatic architecture. A significant



decrease in the serum level of diagnostic enzyme markers (AST, ALT and ALP) was also detected as compared to the positive control group.

As indicated in the present study, the untreated hypercholesterolemic rats had significant decrease in the level of antioxidant enzyme system (CAT, SOD and GPx). Consistent with our results, Kumar *et al.* (2008b) reported that hypercholesterolemia enhanced the free radical generation in various ways. Several studies suggested that disorders of lipid metabolism, hyperlipidemia and obesity are associated with overproduction of oxygen free radicals (Rehman *et al.*, 2003). The enhanced accumulation of these free radicals and dysfunction of antioxidant defense system resulted in oxidative stress (Giao *et al.*, 2008). These radicals can bind covalently to the macromolecules and induce peroxidative degradation of the membrane lipids rich in polyunsaturated fatty acids, leads to the formation of lipid peroxides followed by multiple pathological changes (Shyamala *et al.*, 2003).

The antioxidant activity of Pomegranate components has been the subject of many studies (Naveena *et al.*, 2008; Cam *et al.*, 2009; Mousavinejad *et al.*, 2009; Tezcan *et al.*, 2009). The antioxidant capacity of Pomegranate juice was shown to be three times higher than that of red wine and green tea, based on the evaluation of the free radicals scavenging activity and iron reducing capacity of the juice (Gil *et al.*, 2000). Pomegranate juice was also shown to have significantly higher levels of antioxidants in comparison to commonly consumed fruit juices, such as grape, cranberry, grapefruit, or orange juice (Azadzoi *et al.*, 2005; Rosenblat and Aviram, 2006). The principal antioxidant polyphenols in Pomegranate juice include the ellagitannins and anthocyanins

which have been shown to be the antioxidant responsible for the free radicals scavenging ability of Pomegranate juice (Gil *et al.*, 2000).

Chidambara *et al.* (2002) concluded that Pomegranate extract has also been shown to protect the antioxidant enzymes CAT, GPx and SOD from the effects of toxic chemicals. Turk *et al.* (2008) reported that there was a significant decrease in malondialdehyde (MDA) level and marked increases in reduced glutathione (GSH), GPx and CAT activities, and vitamin C level were observed in rats treated with different doses of Pomegranate juice.

In the present study, Oral administration of Pomegranate juice in doses of 3 and 5 mg/kg b.wt., caused significant increases in activities of CAT, SOD and GPx enzymes when compared to the positive control group. The improvement of CAT, SOD and GPx enzyme activities could be possibly explained by antioxidant properties of Pomegranate juice due to presence of bioactive polyphenolic compounds which play a role in scavenging free radicals and also prevent DNA damage (Fyiad *et al.*, 2012).

Valadares *et al.* (2010) confirmed the ability of Pomegranate extract to protect DNA and preventing chromosomal damage in mice. In addition, Kaur *et al.* (2006) demonstrated that Pomegranate extract afforded up to 60 % protection against hepatic lipid peroxidation due to maintenance of the GSH and serum levels and activities of CAT, GPx and glutathione reductase (GR) enzymes.

## **CHAPTER VI**

# **CONCLUSION AND RECOMMENDATIONS**

## **Chapter VI**

### **Conclusion and Recommendations**

#### **6.1 Conclusion:**

The present study concluded that oral administration of Pomegranate juice at three dosage levels for 28 days to hypercholesterolemic rats reduces body weight gain and feed efficiency ratio; lowers the elevated serum levels of liver enzymes; improves lipid profile and serum level of antioxidant enzymes in hypercholesterolemic rats. These effects are associated with amelioration of degenerative histopathological changes in liver and heart tissues induced by high-cholesterol diet. Therefore, fortification of food products with Pomegranate seeds or drinking of Pomegranate juice may be beneficial for patients who suffer from elevated liver enzymes or hypercholesterolemia or arteriosclerosis or oxidative stress.

## **6.2 Recommendations:**

The study recommended the following:

- 1-** Pomegranate treatment improved lipid profile, increased serum antioxidant levels, improved serum levels of liver enzymes and ameliorated the degenerative changes seen in liver and heart tissues of hypercholesterolemic rats.
- 2-** Patients suffering from hypercholesterolemia and /or cardiovascular disease (CVD) should consume Pomegranate juice because of its health beneficial effect on serum total cholesterol (TC), triglycerides (TG) and LDL-c.
- 3-** Patients suffering from acute hepatitis are advised to consume Pomegranate juice owing to its marked hepatoprotective, excellent antioxidant activities.
- 4-** Encouragement of cultivation of Pomegranate trees in Kingdom of Saudi Arabia and other Arabic countries for increasing production of Pomegranate fruits.
- 5-** Nutritional and health educational programs should be organized and directed to the public to be informed about health benefits of Pomegranate.

## **REFERENCES**

## List of References

- Abdel Moneim, A. E. (2012) Antioxidant activities of *Punica granatum* (pomegranate) peel extract on brain of rats, Journal of Medicinal Plants Research, vol. 6(2): 195-9.
- Abdel Moneim, A. E., Dkhil, M. A. and Al-Quraishy, S. (2011) Studies on the effect of pomegranate (*Punica granatum*) juice and peel on liver and kidney in adult male rats, Journal of Medicinal Plants Research, vol. 5(20): 5083-8.
- Afaq, F., Saleem, M., Krueger, C. G., Reed, J. D. and Mukhtar, H. (2005) Anthocyanin and hydrolyzable tannin-rich pomegranate fruit extract modulates MAPK and NF-kappa B pathways and inhibits skin tumorigenesis in CD-1 mice, International Journal of Cancer, vol. 113(3):423–33.
- Ajaikumar, K. B., Asheef, M., Babu, B. H. and Padikkala, J. (2005) The inhibition of gastric mucosal injury by *Punicagranatum L.* (pomegranate) methanolic extract, Journal of Ethnopharmacology, vol. 96(1-2):171-6.
- Albertini, R., Moratti, R. and De Luca, G. (2002) Oxidation of low-density lipoprotein in atherosclerosis from basic biochemistry to clinical studies, Current Molecular Medicine, vol. 2(6):579-92.
- Allain, C. C., Poon, L. S., Chan, C. S. G., Richmand, W. A. and Fu, P. (1974) Enzymatic Determination of Total Serum Cholesterol, Clinical Chemistry, vol. 20: 470-5.
- Amakura, Y., Okada, M., Tsuji, S. and Tonogai, Y. (2000) High-performance liquid chromatographic determination with photodiode array detection of ellagic acid in fresh and processed fruits, Journal of Chromatography, vol. 896(1-2):87–93.
- Amarowicz, R., Pegg, R. B., Rahimi-Moghaddam, P., Barl, B. and Weil, J. A. (2004) Free-radical scavenging capacity and antioxidant activity of selected plant species from the Canadian prairies, Food Chemistry, vol. 84(4):551–62.

- AHA, American Heart Association (2011) What your cholesterol levels mean, Access date, December 19, 2012, from: <http://www.americanheart.org>.
- Amin, K. A., Kamel, H. H. and Abd Eltawab, M. A. (2011) The relation of high fat diet, metabolic disturbances and brain oxidative dysfunction: modulation by hydroxy citric acid, Lipids in Health and Disease, vol. 14(10):74.
- Annegowda, H. V., Ween, C., Mordi, M. N., Ramanathan, S. and Mansor, S. M. (2010) Evaluation of phenolic content and antioxidant property oh hydrolysed extracts of *Terminalia catappa*. L. leaf, Asian Journal of Plant Sciences, vol. 9(5): 479-485.
- Anoosh, E. G., Mojtaba, E. I. and Fatemeh, S. A. (2010) Study the effect of juice of two variety of pomegranate on decreasing plasma LDL cholesterol, Procedia Social and Behavioral Sciences, vol. 2(2): 620–23.
- Araujo, M. B., Pacce, M. S., Bravo, M., Pugliese, A. M. and Mazza, C. (2011) Severe hypercholesterolemia in children. Presentation of two cases and update of the literature, Archivos Argentinos de pediatria, vol. 109(4):67-71.
- Arhan, M., Ozturk, H. S., Turhan, N., Aytac, B., Guven, M. C., Olcay, E. and Durak, I. (2009) Hepatic oxidant/antioxidant status in cholesterol-fed rabbits: Effects of garlic extract, Hepatology Research, vol. 39(1):70-7.
- Aslam, M. N., Lansky, E. P. and Varani, J. (2006) Pomegranate as a cosmeceutical source: Pomegranate fractions promote proliferation and procollagen synthesis and inhibit matrix metalloproteinase-1 production in human skin cells, Journal of Ethnopharmacology, vol. 103(3):311–8.
- Aviram, M., Dornfeld, L., Rosenblat, M., Volkova, N., Kaplan, M., Coleman, R., Hayek, T., Presser, D. and Fuhrman, B. (2000) Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice, The American Journal of Clinical Nutrition, vol. 71(5):1062–76.
- Aviram, M. and Dornfeld, L. (2001) Pomegranate juice consumption inhibits serum angiotensin-converting enzyme activity and reduces systolic blood pressure, Atherosclerosis, vol. 158(1):195–8.



- Aviram, M., Dornfeld, L., Kaplan, M., Coleman, R., Gaitini, D., Nitecki, S., Hofman, A., Rosenblat, M., Volkova, N., Presser, D., Attias, J., Hayek, T. and Fuhrman, B. (2002) Pomegranate juice flavonoids inhibit low-density lipoprotein oxidation and cardiovascular diseases: studies in atherosclerotic mice and in humans, Drugs under Experimental and Clinical Research, vol. 28(2-3):49-62.
- Aviram, M., Rosenblat, M., Gaitini, D., Nitecki, S., Hoffman, A., Dornfeld, L., Volkova, N., Presser, D., Attias, J., Liker, H. and Hayek, T. (2004) Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation, Clinical Nutrition, vol. 23(3):423–33.
- Azadzoï, K. M., Schulman, R. N., Aviram, M. and Siroky, M. B. (2005) Oxidative stress in arteriogenic erectile dysfunction: prophylactic role of antioxidants, The Journal of Urology, vol. 174(1):386–93.
- Balasundram, N., Sundram, K. and Samman, S. (2006) Phenolic compounds in plants and agri-industrial by-products: antioxidant activity, occurrence, and potential uses, Food Chemistry, vol. 99(1):191–203.
- Bancroft, J. and Gamble, M. (2008) Theory and practice of histological techniques, Edited by: Churchill Livingstone Elsevier, UK: Health Sciences.
- Barzegar, M., Fadavi, A. and Azizi, M. H. (2004) An investigation on the physico-chemical composition of various pomegranates (*Punica granatum L.*) grown in Yazd, Iranian Journal of Food Science and Technology, vol. 1(2):9–14.
- Basu, A. and Penugonda, K. (2009) Pomegranate juice: a heart-healthy fruit juice, Nutrition Reviews, vol. 67(1):49–56.
- Berg, J. M., Tymoczko, J. L. and Stryer, L. (2007) Biochemistry, Edited by: W. H. Freeman and Company, New York.
- Bergmeyer, H. U., Scheibe, P. and Wahlefeld, A. W. (1978) Optimization of methods for aspartate aminotransferase and alanine aminotransferase, Clinical chemistry, vol. 24(1):58-73.
- Bhatnagar, D., Soran, H. and Durrington, P. N. (2008) Hypercholesterolaemia and its management, British Medical Journal, vol. 337: a993.

- Boden, W. E. and Pearson, T. A. (2000) Raising low levels of high-density lipoprotein cholesterol is an important target of therapy, The American Journal of Cardiology, vol. 85(5):645-50.
- Borochoy-Neori, H., Judeinstein, S., Tripler, E., Harari, M., Greenberg, A., Shomer, I. and Holland, D. (2009) Seasonal and cultivar variations in antioxidant and sensory quality of pomegranate (*Punica granatum L.*) fruit, Journal of Food Composition and Analysis, vol. 22(3):189–95.
- Boyer, J. and Liu, R. H. (2004) Apple phytochemicals and their health benefits, Nutrition Journal, vol. 12(3):5.
- Breugnot, C., Iliou, J. P., Privat, S., Robin, F., Vilaine, J. P. and Lenaers, A. (1992) In vitro and ex vivo inhibition of the modification of low-density lipoprotein by indapamide, Journal of Cardiovascular Pharmacology, vol. 20(3):340-7.
- Cam , M., Hisil, Y and Durmaz, G. (2009) Classification of eight pomegranate juices based on antioxidant capacity measured by four methods, Food Chemistry, vol. 112(3):721–6.
- Catapano, A. L. (2009) Perspectives on low-density lipoprotein cholesterol goal achievement, Current Medical Research and Opinion, vol. 25(2):431-47.
- Celik, I., Temur, A. and Isik, I. (2009) Hepatoprotective role and antioxidant capacity of pomegranate (*Punica granatum*) flowers infusion against trichloroacetic acid-exposed rats, Food and Chemical Toxicology, vol. 47(1):145–9.
- Cerda, B., Ceron, J. J., Tomas-Barberan, F. A. and Espin, J. C. (2003) Repeated oral administration of high doses of pomegranate ellagitannin punicalagin to rats for 37 days is not toxic, Journal of Agricultural and Food Chemistry, vol. 51(11):3493-501.
- Chapman, D. G., Castillo, R. and Campbell, J. A. (1959) Evaluation of protein in foods: 1-A Method for the determination of protein efficiency ratio, Canadian Journal of Biochemistry and Physiology, vol. 37(5): 679-86.
- Chalfoun-Mounayar, A., Nemr, R., Yared, P., Khairallah, S. and Chahine, R. (2012) Antioxidant and Weight Loss Effects of Pomegranate Molasses, Journal of Applied Pharmaceutical Science, vol. 2 (6): 45-50.

- Chidambara, M. K. N., Jayaprakasha, G. K and Singh, R. P. (2002) Studies on antioxidant activity of pomegranate (*Punica granatum*) peel extract using in vivo models, Journal of Agricultural and Food Chemistry, vol. 50(17): 4791-5.
- Clifford, M. N. and Scalbert, A. (2000) Review: Ellagitannins—nature, occurrence and dietary burden, Journal of the Science of Food and Agriculture, vol. 80(7):1118–25.
- Davidson, M. H., Maki, K. C., Dicklin, M. R., Feinstein, S. B., Witchger, M. S., Bell, M., McGuire, D. K., Provos, J. C., Liker, H. and Aviram, M. (2009) Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease, The American Journal of Cardiology, vol. 104(7):936–42.
- Di Silvestro, R. A., Di Silvestro, D. J and Di Silvestro, D. J. (2009) Pomegranate extract mouth rinsing effects on saliva measures relevant to gingivitis risk, Phytotherapy Research, vol. 23(8):1123–7.
- Diniz, Y. S., Cicogna, A. C., Padovani, C. R., Santana, L. S., Faine, L. A. and Novelli, E. L. (2004) Diets rich in saturated and polyunsaturated fatty acids: metabolic shifting and cardiac health, Nutrition, vol. 20(2): 230-4.
- Duman, A. D., Ozgen, M., Dayisoğlu, K. S., Erbil, N. and Durgac, C. (2009) Antimicrobial activity of six pomegranate (*Punica granatum L.*) varieties and their relation to some of their pomological and phytonutrient characteristics, Molecules, vol. 14(5):1808–17.
- Durrington, P. (2003) Dyslipidaemia, The Lancet, vol. 362 (9385): 717–31.
- El-Nemr, S. E., Ismail, I. A. and Ragab, M. (1990) Chemical composition of juice and seeds of pomegranate fruit, Die Nahrung, vol. 34(7):601–6.
- El-Rashedy, A. H., Belal, S. K., Osman, H .E. and Shehab, G. M. (2011) Role of Pomegranate on Fatty Liver in Obesity: An Experimental Chemical & Histopathological Study, The Egyptian Journal of Hospital Medicine, vol. 43: 162 – 72.
- Erukainure, O. L., Oke, O. V., Owolabi, F. O., Kayode, F. O., Umanhonlen, E .E. and Aliyu, M. (2012) Chemical properties of *Monodora myristica* and its protective potentials against free radicals in vitro, Oxidants and Antioxidants in Medical Science, vol.1(2): 127- 32.

- Esmailzadeh, A. and Azadbakht, L. (2008) Food intake patterns may explain the high prevalence of cardiovascular risk factors among Iranian women, The Journal of Nutrition, vol. 138(8):1469–75.
- Esmailzadeh, A., Tahbaz, F., Gaieni, I., Alavi-Majd, H., Azadbakht, L. (2004) Concentrated pomegranate juice improves lipid profiles in diabetic patients with hyperlipidemia, Journal of Medicinal Food, vol. 7(3):305-8.
- Esmailzadeh, A., Tahbaz, F., Gaieni, I., Alavi-Majd, H. and Azadbakht, L. (2006) Cholesterol-lowering effect of concentrated pomegranate juice consumption in type II diabetic patients with hyperlipidemia, International Journal for Vitamin and Nutrition Research, vol. 76(3):147–51.
- Fadavi, A., Barzegar, M. and Azizi, H. M.(2006) Determination of fatty acids and total lipid content in oilseed of 25 pomegranates varieties grown in Iran, Journal of Food Composition and Analysis, vol. 19(6):676–80.
- Fadavi, A., Barzegar, M., Azizi, M. H and Bayat, M. (2005) Physicochemical composition of ten pomegranate cultivars (*Punica granatum L.*) grown in Iran, Food Science and Technology International, vol. 11(2):113-9.
- Faria, A., Monteiro, R., Mateus, N., Azevedo, I. and Calhau, C. (2007) Effect of pomegranate (*Punica granatum*) juice intake on hepatic oxidative stress, European Journal of Nutrition, vol. 46(5): 271-8.
- Farrell, G. C. and Larter, C. Z. (2006) Nonalcoholic fatty liver disease: from steatosis to cirrhosis, Hepatology, vol. 43:99-112.
- Forest, C. P., Padma-Nathan, H. and Liker, H. R.(2007) Efficacy and safety of pomegranate juice on improvement of erectile dysfunction in male patients with mild to moderate erectile dysfunction: a randomized, placebo-controlled, double-blind crossover study, International Journal of Impotence Research, vol. 19(6):564–7.
- Frantz, E., Menezes, H. S., Lange, K. C., Abegg, M. P., Correa, C. A., Zangalli, L., Vieira, J. L. and Zettler, C. G. (2012) The effect of maternal hypercholesterolemia on the placenta and fetal arteries in rabbits, Acta Cirurgica Brasileira, vol. 27(1):7-12.

- Fridewald, W. T., Leve, R. I. and Fredrickson, D. S. (1972) Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clinical Chemistry, vol. 18(6): 499-502.
- Fuhrman, B., Volkova, N and Aviran, M. (2005) Pomegranate juice oxidized LDL uptake and cholesterol biosynthesis in macrophages, The Journal of Nutritional Biochemistry, vol. 16(9):570–6.
- Fuhrman, B., Volkova, N. and Aviran, M. (2010) Pomegranate juice polyphenols increase recombinant paraoxonase-1 binding to high-density lipoprotein: studies in vitro and in diabetic patients, Nutrition, vol. 26(4):359–66.
- Fyiad, A. A., Abd El-Kader, M. A. and Abd El-Haleem, A. H. (2012) Modulatory Effects of Pomegranate Juice on Nucleic Acids Alterations and Oxidative Stress in Experimentally Hepatitis Rats, Life Science Journal, vol. 9(3):676-82.
- Galaverna, G., Di Silvestro, G., Cassano, A., Sforza, S., Docena, A., Drioli, E. and Marchelli, R. (2008) A new integrated membrane process for the production of concentrated blood orange juice: effect on bioactive compounds and antioxidant activity, Food Chemistry, vol. 106(3):1021–30.
- Gaziano, M. and Gaziano, T. (2012) Global burden of cardiovascular disease. In P. Robert, O. B., Douglas, L. M., Douglas, P. Z. and Peter, L. (Eds.) Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 8th ed. Philadelphia, PA: Elsevier.
- Gaziano, T. A., Galea, G. and Reddy, K. S. (2007) Scaling up interventions for chronic disease prevention: the evidence, Lancet, vol. 370(9603):1939-46.
- Giao, M. S., Sanjose, G., Muniz, P., Perez, R., Kosinska, M., Pintado, M. E. and Malcata, F. X. (2008) Protection of deoxyribose and DNA from degradation by using aqueous extracts of several wild plants, Journal of Science Food and Agriculture, vol. 88(4): 633-40.
- Gil, M. I., Tomas-Barberan, F. A., Hess-Pierce, B., Holcroft, D. M. and Kader, A. A. (2000) Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing, Journal of Agricultural and Food Chemistry, vol. 48(10):4581–9.
- Glass, C. K. and Witztum, J. L. (2001) Atherosclerosis. The road ahead, Cell, vol. 104(4):503-16.

- Gordon, M. H. (1990) The mechanism of antioxidant action in vitro. in food antioxidants, Edited by: B.J.F. Hudson, London, U.K.
- Gorinstein, S., Leontowicz, H., Leontowicz, M., Drzewiecki, J., Najman, K., Katrich, E., Barasch, D., Yamamoto, K. and Trakhtenberg, S. (2006) Raw and boiled garlic enhances plasma antioxidant activity and improves plasma lipid metabolism in cholesterol-fed rats, Life Sciences, vol. 78(6):655-63.
- Gropper, S., Smith, J. and Groff, J. (2009) Advanced Nutrition and Human Metabolism (5th ed.), Edited by: Belmont, CA: Wadsworth cengage Learning, Canada: Nelson Education Ltd.
- Grundy, S. M., Balady, G. J., Criqui, M. H., Fletcher, G., Greenland, P., Hiratzka, L. F., Houston-Miller, N., Kris-Etherton, P., Krumholz, H. M., LaRosa, J., Ockene, I. S., Pearson, T. A., Reed, J., Washington, R. and Smith, S. C. Jr. (1998) Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association, Circulation, vol. 97 (18): 1876–87.
- Guo, C. , Wei, J., Yang, J., Xu, J., Pang, W. and Jiang Y. (2008) Pomegranate juice is potentially better than apple juice in improving antioxidant function in elderly subjects, Nutrition Research, vol. 28(2):72-7.
- Gurr, M. I., Borlak, N. and Ganatra, S. (1989) Dietary fat and plasma lipids, Nutrition Research Reviews, vol. 2 (1): 63- 86.
- Haidari, M., Ali, M., Casscells, S. W and Madjid, M. (2009) Pomegranate (*Punica granatum*) purified polyphenol extract inhibits influenza virus and has a synergistic effect with oseltamivir, Phytomedicine, vol. 16(12):1127-36.
- Halliwell, B. and Gutteridge, J. (1999) Free Radicals in Biology and Medicine, The 3rd Edited by: Oxford University Press, Oxford.
- Hamad, A. W. and Al-Momene, W. (2009) Separation and purification of crude Ellagic acid from white flesh of pomegranate fruits as a potent anti-carcinogenic, New Biotechnology, vol. 25(1):286.

- Harnafi, H., Aziz, M. and Amrani, S. (2009) Sweet Basil (*Ocimum basilicum* L.) improves lipid metabolism in hypercholesterolemic rats, Journal of Clinical Nutrition and Metabolism, vol. 4(4):181-6.
- Health Statistical Year Book (2010) Kingdom of Saudi Arabia, Ministry of Health, Statistics Directorate. Access date, December 10, 2012, from: <http://www.moh.gov.sa/Ministry/Statistic/book>.
- Heber, D., Seeram, N. P., Wyatt, H., Henning, S. M., Zhang, Y., Ogden, L. G., Dreher, M. and Hill, J. O. (2007) Safety and antioxidant activity of a pomegranate ellagitannin-enriched polyphenol dietary supplement in overweight individuals with increased waist size, Journal of Agricultural and Food Chemistry, vol. 55(24):10050-4.
- Heinecke, J. W. (2006) Lipoprotein oxidation in cardiovascular disease: chief culprit or innocent bystander, The Journal of Experimental Medicine, vol. 203(4):813-6.
- Hossin, F. L. (2009) Effect of Pomegranate (*Punica granatum*) Peels and It's Extract on Obese Hypercholesterolemic Rats, Pakistan Journal of Nutrition, vol. 8 (8):1251-7.
- Howell, W. H., McNamara, D. J., Tosca, M. A., Smith, B. T. and Gaines, J. A. (1997) Plasma lipid and lipoprotein responses to dietary fat and cholesterol: a meta-analysis, The American Journal of Clinical Nutrition, vol.65 (6): 1747-64.
- Huang, T. H., Peng, G., Kota, B. P., Li, G. Q., Yamahara, J., Roufogalis, B. D. and Li, Y. (2005) Pomegranate flower improves cardiac lipid metabolism in a diabetic rat model: role of lowering circulating lipids, British journal of pharmacology, vol. 145(6):767-74.
- Ignarro, L. J., Byrns, R. E, Sumi, D., de Nigris, F. and Napoli, C. (2006) Pomegranate juice protects nitric oxide against oxidative destruction and enhances the biological actions of nitric oxide, Nitric Oxide, vol. 15(2):93-102.
- Insull, W. Jr. (2009) The pathology of atherosclerosis: Plaque development and plaque responses to medical treatment, The American Journal of Medicine, vol. 122(1):3-14.
- Iqbal, M., Kalsoom and Jafri, S. A. (2011) Effect of *Punica granatum* Flowers Extract on Hypercholesterolemic and Alloxan Induced Diabetic Rats, Global Journal of Biotechnology and Biochemistry, vol. 6(2):83-6.

- Ito, M. K., McGowan, M. P. and Moriarty, P. M. (2011) Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia, Journal of Clinical Lipidology, vol. 5 (3): 38–45.
- Jahfar, M., Vijayan, K. K and Azadi, P. (2003) Studies on a polysaccharide from the fruit rind of *Punica granatum*, Research Journal of Chemistry and Environment, vol. 7:43–50.
- Jaiswal, V., DerMarderosian, A., Porter, J. R. (2010) Anthocyanins and polyphenol oxidase from dried arils of pomegranate (*Punica granatum L.*), Food Chemistry, vol. 118(1):11–6.
- James, W. D. and Berger, T. G. (2011) Andrews' Diseases of the Skin: Clinical Dermatology, Edited by: Saunders Elsevier, UK: Health Sciences.
- Jou, J., Choi, S. S. and Diehl, A. M. (2008) Mechanisms of disease progression in nonalcoholic fatty liver disease, Seminars in Liver Disease, vol. 28(4):370-9.
- Jurenka, J. S. (2008) Therapeutic applications of pomegranate (*Punica granatum L.*): a review, Alternative Medicine Review, vol. 13(2):128-44.
- Kakkar, P., Das, B. and Viswanathan, P. N. (1984) A modified spectrophotometric assay of superoxide dismutase, Indian Journal of Biochemistry and Biophysics, vol. 21(2):130-2.
- Kaur, G., Jabbar, Z., Athar, M. and Alam, M. S. (2006) *Punica granatum* (pomegranate) flower extract possesses potent antioxidant activity and abrogates Fe-NTA induced hepatotoxicity in mice, Food and Chemical Toxicology, vol. 44(7):984-93.
- Kaviarasan, S., Naik, G. H., Gangabhairathi, R., Anuradha, C. V. and Priyadarsini, K. I. (2007) In vitro studies on antiradical and antioxidant activities of fenugreek (*Trigonella foenum graecum*) seeds, Food Chemistry, vol. 103(1): 31-37.
- Kong, J. M., Chia, L. S., Goh, N. K., Chia, T. F. and Brouillard, R. (2003) Analysis and biological activities of anthocyanins, Phytochemistry, vol. 64(5):923–33.



- Krajcovicova-Kudlackova, M., Valachovicova, M., Mislanova, C. and Pribiojova, J. (2012) Antioxidative vitamins and oxidative lipid and DNA damage in relation to nutrition, Oxidants and Antioxidants in Medical Science, vol. 1(2): 147-51.
- Kris-Etherton, P. M., Hecker, K. D. and Binkoski, A. E. (2004) Polyunsaturated fatty acids and cardiovascular health, Nutrition Reviews, vol. 62(11): 414-26.
- Krueger, D. A. (2012) Composition of pomegranate juice, Journal of AOAC International, vol. 95(1):163-8.
- Kumar, A. S., Mazumder, A. and Saravanan V. S. (2008a) Antihyperlipidemic activity of *Camellia sinensis* leaves in Triton WR-1339 induced albino rats, Pharmacognosy Magazine, vol. 4(13):60-4.
- Kumar, V., Khan, M. M., Khanna, A. K., Singh, R., Singh, S., Chander, R., Mahdi, F., Mahdi, A. A., Saxena, J. K. and Singh, R. K. (2008b) Lipid Lowering Activity of *Anthocephalus indicus* Root in Hyperlipidemic Rats, Evidence-Based Complementary and Alternative Medicine, vol. 7(3):317-22.
- Kumar, D. S., Muthu, A. K. Smith A. A. and Manavlan R. (2010) Hypolipidemia effect of various extracts of whole plant of *Mucuna pruriens* (Linn) in rat fed with high fat diet, European Journal of Biological Sciences, vol. 2:32-8.
- Kuskoski, M. E., Asuero, G. A., Garcia-Parilla, C. M., Troncoso, M. A. and Fett, R. (2004) Actividad antioxidante de pigmentos antocianicos, Ciencia e Tecnologia de Alimentos, vol. 24(4):691-3.
- Lampe, J. W. (1999) Health effects of vegetables and fruit: assessing mechanisms of action in human experimental studies, The American Journal of Clinical Nutrition, vol. 70(3):475-90.
- Landmesser, U., Hornig, B. and Drexler, H. (2000) Endothelial dysfunction in hypercholesterolemia: mechanisms, pathophysiological importance, and therapeutic interventions, Seminars in Thrombosis and Hemostasis, vol. 26(5): 529-37.
- Langley, P. (2000) Why a pomegranate?, British Medical Journal, vol. 321 (7269): 1153- 4.

- Lansky, E. P. (2006) Beware of pomegranates bearing 40% ellagic Acid, Journal of Medicinal Food, vol. 9(1):119-22.
- Lansky, E. P. and Newman, R. A. (2007) *Punica granatum* (Pomegranate) and its potential for prevention and treatment of inflammation and cancer, Journal of Ethnopharmacology, vol. 109(2):177-206.
- Lee, C. J., Chen, L. G., Liang, W. L. and Wang, C. C. (2010) Anti-inflammatory effects of *Punica granatum* Linne in vitro and in vivo, Food Chemistry, vol. 118:315–22.
- Lee, M. K., Bok, S. H., Jeong, T. S., Moon, S. S., Lee, S. E., Park, Y. B. and Choi, M. S. (2002) Supplementation of naringenin and its synthetic derivative alters antioxidant enzyme activities of erythrocyte and liver in high cholesterol-fed rats, Bioorganic and Medicinal Chemistry, vol. 10(7):2239-44.
- Lei, F., Zhang, X. N., Wang, W., Xing, D. M., Xie, W. D., Su, H. and Du, L. J. (2007) Evidence of anti-obesity effects of the pomegranate leaf extract in high-fat diet induced obese mice, International Journal of Obesity, vol. 31(6):1023-9.
- Li, Y., Guo, C., Yang, J., Wei, J., Xu, J. and Cheng, S. (2006) Evaluation of antioxidant properties of pomegranate peel extract in comparison with pomegranate pulp extract, Food Chemistry, vol. 96(2):254–60.
- Lichtenstein, A. H. (1990) Intestinal cholesterol metabolism, Annals of Medicine, vol. 22 (1): 49–52.
- Longtin, R. (2003) The pomegranate: nature's power fruit?, Journal of the National Cancer Institute, vol. 95(5):346–8.
- Lopes-Virella, M. F., Stone, P., Ellis S. and Colwell, J. A. (1977) Cholesterol Determination in High-Density Lipoproteins Separated by Three Different Methods, Clinical Chemistry, vol. 23(5): 882-4.
- Lu, L. S., Wu, C. C., Hung, L. M., Chiang, M. T., Lin, C. T., Lin, C. W., Su, M. J. (2007) Apocynin alleviated hepatic oxidative burden and reduced liver injury in hypercholesterolaemia, Liver International, vol. 27(4):529-37.

- Ludewing, B., Jaggi, M., Dumrese, T., Brduscha-Riem, K., Odermatt, B., Hengartner, H. and Zinkernagel, R. M. (2001) Hypercholesterolemia exacerbates virus-induced immunologic liver disease via suppression of antiviral cytotoxic T cell responses, The Journal of Immunology, vol.166(5): 3369–76.
- Madrigal-Carballo, S., Rodriguez, G., Krueger, C. G., Dreher, M., Reed, J. D. (2009) Pomegranate (*Punica granatum L.*) supplements: Authenticity, antioxidant and polyphenol composition, Journal of Functional Foods, vol. 1:324–9.
- Manach, C., Mazur, A. and Scalbert, A. (2005) Polyphenols and prevention of cardiovascular diseases, Current Opinion in Lipidology, vol. 16(1):77-84.
- Margoni, A., Perrea, D. N., Vlachos, I., Prokopaki, G., Pantopoulou, A., Fotis, L., Kostaki, M. and Papavassiliou, A. (2011) Serum Leptin, Adiponectin and Tumor Necrosis Factor- $\alpha$  in Hyperlipidemic Rats with/without Concomitant Diabetes Mellitus, The Feinstein Institute for Medical Research, vol. 17( 1-2): 36-40.
- Marin, F. R., Martinez, M., Uribesalgo, T., Castillo, S. and Frutos, M. J. (2002) Changes in nutraceutical composition of lemon juices according to different industrial extraction systems, Food Chemistry, vol.78(3):319–24.
- Matos, S. L., Paula, H., Pedrosa, M. L., Santos, R. C., Oliveira, E. L., Chianca, Jr. D. A. and Silva, M. E. (2005) Dietary models for inducing hypercholesterolemia in rats, Brazilian Archives of Biology and Technology, vol. 48 (2): 203-209.
- Mattson, F. H. and Grundy, S. M. (1985) Comparison of effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on plasma lipids and lipoproteins in man, Journal of Lipid Research, vol. 26(2):194-202.
- Mirdehghan, S. H. and Rahemi, M. (2007) Seasonal changes of mineral nutrients and phenolics in pomegranate (*Punica granatum L.*) fruit, Scientia Horticulturae, vol. 111(2):120– 7.
- Miura, T., Muraoka, S. and Fujimoto, Y. (2000) Inactivation of creatine kinase by Adriamycin during interaction with horseradish peroxidase, Biochemical pharmacology, vol. 60(1):95-9.
- Mohan, M., Waghulde, H. and Kasture, S. (2010) Effect of pomegranate juice on Angiotensin II-induced hypertension in diabetic Wistar rats, Phytotherapy Research, vol. 2:196-203.

- Molgaard, J., von Schenck, H., Olsson, A. G. (1989) Comparative effects of simvastatin and cholestyramine in treatment of patients with hypercholesterolaemia, European Journal of Clinical Pharmacology, vol. 36(5):455-60.
- Mousavinejad, G., Emam-Djomeh, Z., Rezaei, K. and Khodaparast, M. H. H. (2009) Identification and quantification of phenolic compounds and their effects on antioxidant activity in pomegranate juices of eight Iranian cultivars, Food Chemistry, vol. 115:1274-8.
- Must, A., Spadano, J., Coakley, E. H., Field, A. E., Colditz, G. and Dietz, W. H. (1999) The disease burden associated with overweight and obesity, Journal of the American Medical Association, vol. 282(16):1523-9.
- Mustafa, R. A., Abdul Hamid, A., Mohamed, S. and Bakar, F. A. (2010) Total phenolic compounds, flavonoids, and radical scavenging activity of 21 selected tropical plants, Journal of Food Science, vol. 75(1):28-35.
- Narr Ben, C., Ayed, N. and Metche, M. (1996) Quantitative determination of the polyphenolic content of pomegranate peel, Zeitschrift für Lebensmittel-Untersuchung und –Forschung, vol. 203(4):374-8.
- Naveena, B. M., Sen, A. R., Kingsly, R. P., Singh, D. B. and Kondaiah, N. (2008) Antioxidant activity of pomegranate rind powder extract in cooked chicken patties, International Journal of Food Science and Technology, vol. 43(10):1807-12.
- Negi, P. S. and Jayaprakasha, G. K. (2003) Antioxidant and antibacterial activities of *Punica granatum* peel extracts, Journal of Food Science, vol. 68(4):1473-7.
- Noda, Y., Kaneyuka, T., Mori, A. and Packer, L. (2002) Antioxidant activities of pomegranate fruit extract and its anthocyanidins: delphinidin, cyanidin, and pelargonidin, Journal of Agricultural and Food Chemistry, vol. 50(1):166-71.
- Nwozo, S. O., Orojobi, B. F. and Adaramoye, O. A. (2011) Hypolipidemic and antioxidant potentials of *Xylopiya aethiopica* seed extract in hypercholesterolemic rats, Journal of Medicinal Food, vol. 14(1-2):114-9.

- Oh, B., Kim, S. Y., Kim, D. J., Lee, J. Y., Lee, J. K., Kimm, K., Park, B. L., Shin, H. D., Kim, T. H., Park, E. K., Koh, J. M. and Kim, G. S. (2007) Associations of catalase gene polymorphisms with bone mineral density and bone turnover markers in postmenopausal women, Journal of Medical Genetics , vol. 44(1): 62.
- Opara, U. L. and Al-Ani, M. R. (2010) Antioxidant contents of pre-packed fresh-cut versus whole fruit and vegetables, British Food Journal, vol. 112 (8):797 – 810.
- Opara, U. L., Al-Ani, M. R. and Al-Shuaibi, Y. S. (2009) Physico-chemical properties, vitamin C content and antimicrobial properties of pomegranate fruit (*Punica granatum* L.), Food Bioprocess Technology, vol. 2(3):315-21.
- Osman, H. F., Eshak, M. G., El-Sherbiny, E. M. and Bayoumi, M. M. (2012) Biochemical and Genetical Evaluation of Pomegranate Impact on Diabetes Mellitus Induced by Alloxan in Female Rats, Life Science Journal, vol. 9(3): 1543-53.
- Otunola, G. A., Oyelola, B., Adenike, O., Oladiji, T. and Afolayan, A. A. (2010) Effects of diet-induced hypercholesterolemia on the lipid profile and some enzyme activities in female Wistar rats, African Journal of Biochemistry Research, vol. 4 (6):149-54.
- Ozgul-Yucel, S. (2005) Determination of conjugated linolenic acid content of selected oil seeds grown in Turkey, Journal of the American Oil Chemists' Society, vol. 82(12):893– 7.
- Paglia, D. E. and Valentine, W. N. (1967) Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase, The Journal of Laboratory and Clinical Medicine, vol. 70(1):158- 69.
- Pendino, G. M., Mariano, A., Surace, P., Caserta, C. A., Fiorillo, M. T., Amante, A., Bruno, S., Mangano, C., Polito, I., Amato, F., Cotichini, R., Stroffolini, T. And Mele, A. (2005) Collaborating Group ACE. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town, Hepatology, vol. 41: 1151–9.
- Pentikainen, M. O., Lindstedt, K. A. and Kovanen, P. T. (1995) Inhibition of the oxidative modification of LDL by nitecapone, Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15(6):740-7.

- Pin-Der, D. (1998) Antioxidant activity of burdock (*Arctium lappa L.*): It's scavenging effects on free radical and active oxygen, Journal of the American Oil Chemists' Society, vol. 75(4):455–61.
- Poyrazoglu, E., Gokmen, V. and Artık, N. (2002) Organic acids and phenolic compounds in pomegranates (*Punica granatum L.*) grown in Turkey, Journal of Food Composition and Analysis, vol. 15(5):567–75.
- Prasad, K. (2010) Effects of vitamin E on serum enzymes and electrolytes in hypercholesterolemia, Molecular and Cellular Biochemistry, vol. 335(1-2):67-74.
- Puskas, L. G., Nagy, Z. B., Giricz, Z., Onody, A., Csonka, C., Kitajka, K., Hackler, L. Jr., Zvara, A. and Ferdinandy, P. (2004) Cholesterol diet-induced hyperlipidemia influences gene expression pattern of rat hearts: a DNA microarray study, Federation of European Biochemical Societies Letters, vol. 562(1-3):99-104.
- Ramachandran, H. D., Narasimhamurthy, K. and Raina, P. L. (2003) Modulation of cholesterol induced hypercholesterolemia through dietary factors in Indian desert gerbils (*Meriones hurrianae*), Nutrition Research, vol. 23(2): 245-256.
- Reeves, P. G., Nielsen, F. H. and Fahey, G. C. Jr. (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet, The Journal of Nutrition, vol. 123(11):1939–51.
- Rehman, S., Mahdi, A. and Hasan, M. (2003) Trace Metal-induced Lipid Peroxidation in Biological system, The society for Free Radical Resaerch-India Bulletin, vol. 2(2): 12-8.
- Reuter, S., Gupta, S. C., Chaturvedi, M. M. and Aggarwal, B. B. (2010) Oxidative stress, inflammation, and cancer: how are they linked?, Free Radical Biology and Medicine, vol. 49(11):1603-16.
- Rice-Evans, C. A., Miller, N. J. and Paganga, G. (1996) Structure-antioxidant activity relationships of flavonoids and phenolic acids, Free Radical Biology and Medicine, vol. 20(7):933-56.

- Rosenblat, M. and Aviram, M. (2006) Anti-oxidative properties of pomegranate: In vitro studies, Edited by: Seeram, N.P., Heber, D. Pomegranates: ancient roots to modern medicine, New York: Taylor and Francis Group.
- Rosenblat, M. and Aviram, M. (2011) Pomegranate juice protects macrophages from triglyceride accumulation: inhibitory effect on DGAT1 activity and on triglyceride biosynthesis, Annals of Nutrition & Metabolism, vol. 58(1):1-9.
- Rosenblat, M. , Volkova, N., Coleman, R. and Aviram, M. (2006) Pomegranate byproduct administration to apolipoprotein e-deficient mice attenuates atherosclerosis development as a result of decreased macrophage oxidative stress and reduced cellular uptake of oxidized low-density lipoprotein, Journal of Agricultural and Food Chemistry, vol. 54(5):1928-35.
- Sacks, F. M. and Katan, M. (2002) Randomized clinical trials on the effects of dietary fat and carbohydrate on plasma lipoproteins and cardiovascular disease, The American Journal of Medicine, vol. 113 (9): 13–24.
- Saini, H. K., Arneja, A. S. and Dhalla, N. S. (2004) Role of cholesterol in cardiovascular dysfunction, The Canadian Journal of Cardiology, vol. 20(3):333- 46.
- Saki, N., Saki, G., Rahim, F., khoozani, A. S. and Nikakhlagh, S. (2011) Modulating effect of soy protein on serum cardiac enzymes in cholesterol-fed rats, International Journal of Medicine and Medical Sciences, vol. 3(14): 390-5.
- Schaefer, E. J. (2010) Introduction to High-Density Lipoprotein, Dyslipidemia, and Coronary Heart Disease, in High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease, Edited by: Springer Science, New York: Business Media, LLC.
- Schwab, K., Neumann, B., Vignon-Zellweger, N., Fischer, A., Stein, R., Jungblut, P. R., Scheler, C. and Theuring, F. (2011) Dietary phytoestrogen supplementation induces sex differences in the myocardial protein pattern of mice: a comparative proteomics study, Proteomics, vol. 11(19):3887–904.
- Schwedhelm, E., Maas, R., Troost, R. and Boger, R. H. (2003) Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress, Clinical Pharmacokinetics, vol. 42(5): 437-59.

- Schwenke, D. C. and Behr, S. R. (1998) Vitamin E combined with selenium inhibits atherosclerosis in hypercholesterolemic rabbits independently of effects on plasma cholesterol concentrations, Circulation Research, vol. 83(4):366-77.
- Seeram, N. P., Aviram, M., Volkova, N., Zhang, Y., Henning, S. M., Nair, M. and Heber, D. (2004a) Dietary polyphenols derived from pomegranates are potent antioxidants: evaluation in various in vitro models of antioxidation. In: 228th National Meeting of the American Chemical Society, American Chemical Society, Philadelphia, PA.
- Seeram, N. P., Lee, R. and Heber, D. (2004b) Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (*Punica granatum L.*) juice, International Journal of Clinical Chemistry, vol. 348(1-2):63-8.
- Seeram, N. P., Adams, L. S., Henning, S. M., Niu, Y., Zhang, Y., Nair, M. G. and Heber, D. (2005a) *In vitro* antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice, The Journal of Nutritional Biochemistry, vol. 16(6):360-7.
- Seeram, N. P., Lee, R., Hardy, M., Heber, D. (2005b) Rapid large-scale purification of ellagitannins from pomegranate husk, a by-product of the commercial juice industry, Separation and Purification Technology, vol. 41(1):49-55.
- Seeram, N. P., Schulman, R. N., Heber, D. (2006) Pomegranates: Ancient roots to modern medicine, Edited by: R. Hardman, New York: Taylor and Francis CRC Press.
- Seeram, N. P., Aviram, M., Zhang, Y., Henning, S. M., Feng, L., Dreher, M. and Heber, D. (2008) Comparison of antioxidant potency of commonly consumed polyphenol-rich beverages in the United States, Journal of Agricultural and Food Chemistry, vol. 56(4):1415-22.
- Sendur, O. F., Turan, Y., Tastaban, E. and Serter, M. (2009) Antioxidant status in patients with osteoporosis: A controlled study, Joint Bone Spine, vol. 76(5): 514-8.
- Sezer, E. D., Akcay, Y. D., Ilanbey, B., Yildirim, H. K. and Sozmen, E. Y. (2007) Pomegranate wine has greater protection capacity than red wine on low-density lipoprotein oxidation, Journal of Medicinal Food, vol. 10(2):371-4.



- Sezer, E.D., Sozmen, E.Y., Nart, D. and Onat, T. (2011) Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation, Vascular Health and Risk Management, vol. 7:333-43.
- Shanmugasundaram, K. R., Visvanathan, A., Dhandapani, K., Srinivasan, N., Rasappan, P., Gilbert, R., Alladi, S., Kancharla, S. and Vasanthi, N. (1986) Effect of high-fat diet on cholesterol distribution in plasma lipoproteins, cholesterol esterifying activity in leucocytes, and erythrocyte membrane components studied: importance of body weight, The American Journal of Clinical Nutrition, vol. 44(6):805-15.
- Shields, C. and Shields, J. (2008) Eyelid, conjunctival, and orbital tumors: atlas and textbook, Edited by: Hagerstown, Maryland: Lippincott Williams & Wilkins.
- Shinnick, F. L., Ink, S. L. and Marie, J. A. (1990) Dose response to a dietary oat bran fraction in cholesterol-fed rats, The Journal of Nutrition, vol. 120(6): 561-8.
- Shyamala, M. P., Venukumar, M. R. and Latha, M. S. (2003) Antioxidant potential of the syzygium Aromaticum (Gaert.) Linn. (Cloves) in rats fed with high fat diet, Indian Journal of Pharmacology, vol. 35: 99-103.
- Sibley, C. and Stone, N. J. (2006) Familial hypercholesterolemia: a challenge of diagnosis and therapy, Cleveland Clinic Journal of Medicine, vol. 73(1):57-64.
- Singh, M., Arseneault, M., Sanderson, T., Morthy, V. and Ramassamy, C. (2008) Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism and cellular and molecular mechanism, Journal of Agricultural and Food Chemistry, vol. 56(13):4855-73.
- Singh, R. P., Murthy, K. N. C. and Jayaprakasha, G. K. (2002) Studies on the antioxidant activity of pomegranate peel and seed extracts using in vitro models, Journal of Agricultural and Food Chemistry, vol. 50(1):81-6.
- Singh, U., Devaraj, S. and Jialal, I. (2005) Vitamin E, oxidative stress, and inflammation, Annual Review of Nutrition, vol. 25:151-74.
- Singleton, V. L. and Rossi, J. A. (1965) Colorimetry of total phenolics with phosphomolybdic-phosphotungstic acid reagents, American Journal of Enology and Viticulture, vol. 16(3):144-58.

- Sinha, A. K. (1972) Colorimetric Assay of Catalase, Analytical Biochemistry, vol. 47(2):389 - 94.
- Sonmez, M., Turk, G. and Yuce, A. (2005) The effect of ascorbic acid supplementation on sperm quality, lipid peroxidation and testosterone levels of male Wistar rats, Theriogenology, vol. 63(7):2063-72.
- Soobrattee, M. A., Neergheen, V. S., Luximon-Ramma, A., Aruoma, O. I. and Bahorun, T. (2005) Phenolics as potential antioxidant therapeutic agents: mechanism and actions, Mutation Research, vol. 579(1-2):200–13.
- Stocker, R. and Keaney, J. F, Jr. (2004) Role of oxidative modifications in atherosclerosis, Physiological Reviews, vol. 84(4):1381-478.
- Sudheesh, S. and Vijayalakshmi, N. R. (2005) Flavonoids from *Punica granatum*--potential antiperoxidative agents, Fitoterapia, vol. 76(2):181-6.
- Sumner, M. D., Elliott-Eller, M., Weidner, G., Daubenmeier, J. J., Chew, M. H., Marlin, R., Raisin, C. J. and Ornish, D. (2005) Effects of pomegranate juice consumption on myocardial perfusion in patients with coronary heart disease, The American Journal of Cardiology, vol. 96(6):810–4.
- Suo, J. L., Peng, Y., Zhang, Z. Y. and Wang, M. L. (2009) Studies on the optimum extraction and antioxidative activity of total flavonoids from *punica granatum* leaves, Biotechnology, vol. 19: 63-65.
- Syed, D. N., Afaq, F. and Mukhtar, H. (2007) Pomegranate derived products for cancer chemoprevention, Seminars in Cancer Biology, vol. 17(5):377–85.
- Tebib, K., Rouanet, J. M., Besançon, P. (1994) Effect of grape seed tannins on the activity of some rat intestinal enzyme activities, Enzyme and Protein, vol. 48(1):51-60.
- Tezcan, F., Gultekin-Ozguven, M., Diken, T., Ozcelik, B. and Erim, F. B. (2009) Antioxidant activity and total phenolic, organic acid and sugar content in commercial pomegranate juices, Food Chemistry, vol. 115(3):873–7.

- Toklu, H. Z., Dumlu, M. U., Sehirlı, O., Ercan, F., Gedik, N., Gökmen, V., Sener, G. (2007) Pomegranate peel extract prevents liver fibrosis in biliary-obstructed rats, The Journal of Pharmacy and Pharmacology, vol. 59(9):1287-95.
- Tous, M., Ferre, N., Camps, J., Riu, F. and Joven, J. (2005) Feeding apolipoprotein E-knockout mice with cholesterol and fat enriched diets may be a model of non-alcoholic steatohepatitis, Molecular and Cellular Biochemistry, vol. 268(1-2): 53–8.
- Trinder, P. (1969) Triglycerides estimation by GPO-PAP method, Annals of Clinical Biochemistry, vol. 6: 24-7.
- Turk, G., Sonmez, M., Aydin, M., Yuce, A., Gur, S., Yuksel, M., Aksu, E. H. and Aksoy, H. (2008) Effects of pomegranate juice consumption on sperm quality, spermatogenic cell density, antioxidant activity and testosterone level in male rats, Clinical Nutrition, vol. 27(2):289-96.
- Tzulker, R., Glazer, I., Bar-Ilan, I., Holland, D., Aviram, M. and Amir, R. (2007) Antioxidant activity, polyphenol content and related compounds in different fruit juices and homogenates prepared from 29 different pomegranate accessions, Journal of Agricultural and Food Chemistry, vol. 55(23):9559–70.
- Valadares, M. C., Pereira, E. R. T., Benfıca, P. L. and Paula, J. R. (2010) Assessment of mutagenic and antimutagenic effects of *Punica granatum* in mice, Brazilian Journal of Pharmaceutical Sciences, vol. 46(1): 121-7.
- Van Elswijk, D. A., Schobel, U. P., Lansky, E. P., Irth, H. and Van der Greef, J. (2004) Rapid dereplication of estrogenic compounds in pomegranate (*Punica granatum*) using on-line biochemical detection coupled to mass spectrometry, Phytochemistry, vol. 65(2):233–41.
- Vidal, A., Fallarero, A., Pena, B. R., Medina, M. E., Gra, B., Rivera, F., Gutierrez, Y. and Vuorela, P. M. (2003) Studies on the toxicity of *Punica granatum L.* (Punicaceae) whole fruit extracts, Journal of Ethnopharmacology, vol. 89(2-3):295–300.
- Vincent, H. and Taylor, A. (2006) Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans, International Journal of Obesity, vol. 30(3):400-18.

- Viuda-Martos, M., Ruiz-Navajas, Y., Fernandez-Lopez, J. and Perez-Alvarez, J. A. (2011) Spices as functional foods: a review, Critical Reviews in Food Science and Nutrition, vol. 51(1):13-28.
- Waheed, S., Siddique, N., Rahman, A., Zaidi, J. H. and Ahmad S. (2004) INAA for dietary assessment of essential and other trace elements in 14 fruits harvested and consumed in Pakistan, Journal of Radioanalytical and Nuclear Chemistry, vol. 260(3):523-31.
- Wang, R. F., Xiang, L., Du, L. J. and Wang, W. (2006) The constituents of punica granatum, Asia-Pacific Traditional Medicine, vol. (3): 61-71.
- Wang, X., Hasegawa, J., Kitamura, Y., Wang, Z., Matsuda, A., Shinoda, W., Miura, N. and Kimura, K. (2011) Effects of hesperidin on the progression of hypercholesterolemia and fatty liver induced by high-cholesterol diet in rats, Journal of Pharmacological Sciences, vol. 117(3):129-38.
- Wang, Z. Y. and Chen, X. Q. (2004) Functional evaluation for effective compositions in seed oil of Korean pine, Journal of Forestry Research, vol. 15(3): 215-7.
- Willcox, J. K., Ash, S. L. and Catignani, G. L. (2004) Antioxidants and prevention of chronic disease, Critical Reviews in Food Science and Nutrition, vol. 44(4):275-95.
- Witztum, J. L. and Steinberg, D. (2001) The oxidative modification hypothesis of atherosclerosis: does it hold for humans?, Trends in Cardiovascular Medicine, vol. 11(3-4):93-102.
- WHO, World Health Organization (2008) Cardiovascular diseases (CVDs), Access date, December 17, 2012, from: <http://www.who.int/mediacentre>.
- Xu, K. Z., Zhu, C., Kim, M. S., Yamahara, J. and Li, Y. (2009) Pomegranate flower ameliorates fatty liver in an animal model of type 2 diabetes and obesity, Journal of Ethnopharmacology, vol. 123(2):280-7.
- Yudi, M., Omera, L., McCubbery, N., Dick, S., Jayasinghe, R. and Hamilton-Craig, I. (2012) Suboptimal consideration and management of potential familial hypercholesterolaemia in patients with suspected premature coronary artery disease, Singapore Medical Journal, vol. 53(3):174-8.

Yugarani, T., Tan, B. K., the, M. and Das, N. P. (1992) Effects of polyphenolic natural products on the lipid profiles of rats fed high fat diets, Lipids, vol. 27(3):181-6.

Zech, L. A. Jr. and Hoeg, J. M. (2008) Correlating corneal arcus with atherosclerosis in familial hypercholesterolemia, Lipids in Health and Disease, vol. 7: 7.

Zuliani, G. and Renato, F. (2003) Autosomal recessive hypercholesterolemia: Genetics and clinical aspects, International Congress Series, vol. 1253:73-7.

# **ARBIC SUMMARY**

# تأثير عصير الرمان على صور ليبيدات الدم والإنزيمات المضادة للأكسدة لدى الفئران المصابة بارتفاع الكولسترول

منال معلا المورعي

الملخص العربي

استهدفت الدراسة الحالية تأثير تناول عصير الرمان بثلاث جرعات عن طريق الفم لمدة 28 يوم للفئران المصابة بارتفاع مستوى الكولسترول بالدم. وشملت هذه التأثيرات الوزن النسبي للجسم، نسبة كفاءة الغذاء، والأوزان النسبية لبعض الأعضاء الداخلية (الكبد والقلب) و مستوى إنزيمات الكبد في سيرم الدم، صورة دهون الدم، ومستوى الإنزيمات المضادة للأكسدة في أنسجة الكبد المجانسة، وكذلك الفحص الهستوباثولوجي لأنسجة الكبد والقلب.

و تم تطبيق الدراسة على 35 فأر ذكر بالغ من فصيلة الألبينو ويستر، تم توزيعها إلى خمس مجموعات بالتساوي، وكانت المجموعة الأولى ضابطة سالبة، تناولت على الغذاء الأساسي. أما المجموعات الأربعة الأخرى تناولت غذاء مدعم بنسبة 2 % كولسترول لإحداث ارتفاع في كولسترول الدم لهذه الفئران. وتركت إحداها مجموعة ضابطة موجبة (مصابة بارتفاع كولسترول الدم)، وتم إعطاء المجموعات الثلاثة الأخرى عصير الرمان عن طريق الفم بثلاثة جرعات هي 1، 3 و 5 مل/كجم من وزن الجسم على التوالي وذلك لمدة 28 يوم. تم حساب

أوزان الفئران قبل بدء التجربة وفي نهايتها لمعرفة معدل الزيادة النسبية في وزن الجسم، وكذلك حساب كمية الغذاء المستهلك يوميا وحساب نسبة كفاءة الغذاء. وفي نهاية فترة التجربة تم أخذ عينات من الدم لإجراء التحليلات البيوكيميائية، وحساب الوزن النسبي لبعض الأعضاء الداخلية، وكذلك تم أخذ الكبد والقلب لإجراء الفحص الهستوباثولوجي.

وأظهرت النتائج أن تناول عصير الرمان عن طريق الفم للفئران المصابة بارتفاع مستوى الكولسترول بالدم قد أدى إلى نقص معنوي في الوزن النسبي للجسم، نسبة كفاءة الغذاء ومستويات إنزيمات الكبد، الكولسترول الكلي، الجليسيريدات الثلاثية و الكولسترول المنخفض الكثافة والكولسترول المنخفض الكثافة جدا، بينما أدى إلى زيادة معنوية في نشاط الإنزيمات المضادة للأكسدة. وقد أظهر الفحص الهستوباثولوجي لأنسجة الكبد والقلب وجود تحسن واضح يعتمد على الجرعة المعطاة في التغيرات الهستوباثولوجية (المرضية) التي سببها الكولسترول المرتفع بهذه الأنسجة.

وتدل نتائج هذه الدراسة أن عصير الرمان له تأثيرات علاجية هامة وهي تأثير خافض لإنزيمات الكبد المرتفعة، وخافض للكولسترول والدهون الثلاثية ومضاد للأكسدة في الفئران المصابة بارتفاع كوليسترول الدم. وتوصى هذه الدراسة بأن تناول عصير الرمان الطازج قد يكون مفيدا للمرضى الذين يعانون من ارتفاع إنزيمات الكبد وارتفاع الكوليسترول والجليسيريدات الثلاثية وكذلك في حالات الإجهاد التأكسدي.





# تأثير عصير الرمان على صور ليبيدات الدم والإنزيمات المضادة للأكسدة لدى الفئران المصابة بارتفاع الكولسترول

منال معلا دغليب المورعي

بحث مقدم لنيل درجة الماجستير في الإقتصاد المنزلي (الغذاء والتغذية)

تحت إشراف

د. ريهام أبو المحاسن عرفات د. أماني عليوي الرشيدى

كلية الاقتصاد المنزلي

جامعة الملك عبد العزيز

جدة - المملكة العربية السعودية

رجب 1434هـ - مايو 2013 م (18/7/1434هـ)



# تأثير عصير الرمان على صور ليبيدات الدم والإنزيمات المضادة للأكسدة لدى الفئران المصابة بارتفاع الكولسترول

منال معلا دغليب المورعي

بحث مقدم لنيل درجة الماجستير في الإقتصاد المنزلي (الغذاء والتغذية)

كلية الاقتصاد المنزلي  
جامعة الملك عبد العزيز-جدة  
رجب 1434هـ- مايو 2013 م